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Abstract 
Engineering of Inhalation Aerosols Combining Theophylline 
and Budesonide 
Chi Chen 
Keywords: inhalation, combination particles, inhalable theophylline, budesonide, 
particle engineering, experimental design. 
In asthma therapy, the use of theophylline to prevent bronchial spasm and 
glucocorticoids to decrease inflammation is widely indicated. Apart from the acute 
asthma attack oral theophylline is treated for chronic therapy in order to minimize 
inflammation and to enhance the efficiency of corticosteroids and recover 
steroids’ anti-inflammatory actions in COPD treatment. The preferred application 
route for respiratory disease treatment is by inhalation, such as dry powder 
inhalers (DPI) being the delivery systems of first choice. As shown recently, there 
is an advantageous effect if the drugs are given simultaneously which is caused 
by a synergistic effect at the same target cell in the lung epithelia. Therefore, it 
seems rational to combine both substances in one particle. This type of particle 
has the advantage over a combination product containing both drugs in a physical 
mixture which occurs rather randomly deposition leading to API segregation and 
non-dose-uniformity. 
Dry powder inhalers (DPIs) is a type of therapeutic pharmaceutical formulations 
usually present in the solid form. Due to the nature of the solid-state, an 
understanding of chemical and physical properties must be established for 
acquiring optimum performance of the active pharmaceutical ingredients (APIs). 
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In recent year, generation of DPIs is a destructive procedure to meet the micron 
size. Such processes are inefficient and difficult to control. Moreover, according 
to current researches on combination APIs formulation, this type of DPIs 
performed a greater variability in does delivery of each active, leading to poor 
bioavailability and limit clinical efficient. This result suggest that combination 
formulations require advanced quality and functionality of particles with suitable 
physicochemical properties. Hence, in order to production of binary and 
combination DPIs products, the aim of this study was to develop the spray drying 
and ultrasonic process for engineering of combination drug particles that will be 
delivered more efficiently and independently of dose variations to the lung. 
Microparticles were produced by spray drying or/and ultrasonic technique. The 
processing parameters and addition of excipients (polymers) were optimized 
using a full factorial design such that microparticles were produced in a narrow 
size range suitable for inhalation. Employing excipients resulted in high saturation 
environment leading to minimized sphere particles when compared to 
conventional solvent. Solid state characterization of microparticles using powder 
x-ray diffraction and differential scanning calorimetry indicated that the particles 
contained crystalline but no cocrystal. The combination particles comparable to 
or better than micronized drug when formulated as a powder blended with lactose. 
It was concluded that the use of HPMC enhanced crystallinity suitable for 
inhalation; and combination particles improved uniform distribution on the stage 
of NGI.  
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Chapter 1 : Introduction  
1.1 Chronic obstructive pulmonary disease (COPD) 
Chronic obstructive pulmonary disease (COPD) is a syndrome of progressive 
airflow limitation caused by chronic inflammation of the airways and lung 
parenchyma (Sutherland and Cherniack, 2004). It is characterized by airflow 
obstruction. The airflow obstruction is usually progressive and not fully 
reversible(NHS, 2004). The term of COPD includes two main conditions- chronic 
bronchitis and emphysema (NHS, 2010). Chronic bronchitis is a chronic 
inflammation of bronchi in the lung; and emphysema is a long-term, progressive 
disease of the lungs, which can cause physical damage to the shape and function 
of lungs. Both of two diseases can be caused by smoking tobacco, which is the 
one of risk factors of COPD. In addition, gene, airway hyperresponsiveness, lung 
growth, occupational dust and chemicals, air pollutions and infections all are 
related to the causes of COPD(NHS, 2010).  
Current treatments for COPD are aimed at increasing airflow, decreasing 
respiratory symptoms, decreasing exacerbations, and improving the quality of life 
(Bateman et al., 2008). The antimuscarinics, methylxanthines, short-acting and 
long-acting bronchodilators and corticosteroids are commonly used as single 
therapeutic or in combination to treat patients with COPD (Albert and Calverley, 
2008, Lasseter et al., 2011). 
The methylxanthines, such as theophylline, have been used in the treatment of 
COPD for many years. Recent studies suggest that theophylline can improve lung 
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and diaphragmatic muscle function, thereby reducing COPD symptoms (Barnes, 
2006).  
Bronchodilators also can be grouped into long/short acting β2-adrenergic-
receptor agonists, and muscarinic receptor antagonist (Albert and Calverley, 
2008, Moulton and Fryer, 2011). Their primary therapeutic effects are increase of 
lung function and decrease of dyspnoea and other COPD symptoms. In a clinical 
study, it was found that β2- agonists significantly reduced exacerbations and 
improved a health-related quality of life (HRQOL) in patients with COPD (Cazzola 
et al., 2010).  Recently , long acting β2-agonists, for example salmeterol xinafoate 
and formoterol fumarate, have been recommended as first-line maintenance 
therapy in the treatment of COPD (Bateman et al., 2008).  Recent studies also 
suggested that combination therapy of a corticosteroid and a long acting β2- 
agonist have been very successful in managing asthma and COPD (Wouters et 
al., 2005, Miller-Larsson and Selroos, 2006, Greening et al., 1994, Calverley et 
al., 2003, Szafranski et al., 2003, Cazzola and Hanania, 2006).   
Corticosteroids are recommended in step 2 of the British Thoracic Society’s (BTS) 
guidelines for the treatment of chronic asthma (Bateman et al., 2008, BTS, 2011), 
but their role in COPD is controversial. A number of studies have shown steroids 
alleviate patients’ symptoms, reduce the exacerbation rate, and improve health 
status in patients with COPD or asthma (Vestbo et al., 1999, Sutherland et al., 
2003). However, it has also been reported (Sutherland et al., 2003, Wouters et 
al., 2005) that steroids do not substantially modify airway inflammation in COPD; 
and compared to placebo, there is no appreciable improvement of lung function 
with steroid therapy. In addition, corticosteroids provide less benefit to the 
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patients who smoke (Chaudhuri et al., 2003, Ito et al., 2001, Vestbo et al., 1999). 
This suggests that there could be corticosteroid-resistance in some patients with 
COPD. Recently, studies have reported that a combination of corticosteroid with 
theophylline is superior to placebo or steroid monotherapy with regard to lung 
function, anti-inflammation in airway, symptoms, frequency of exacerbation and 
health status in COPD (Spears et al., 2009, Lim et al., 2000, Barnes, 2003, Ford 
et al., 2010). This may suggest that theophylline can help reduce steroid 
resistance and enhance anti-inflammatory activity in COPD.  
1.2 Treatment of COPD  
1.2.1 Methylxanthines 
Theophylline is a xanthine, which has been recognized as third-line agent in 
asthma and COPD therapy according to international guidelines (Bateman et al., 
2008).  This is because of its unacceptable side effects. Many patients treated 
with theophylline experience nausea, headaches, vomiting, abdominal discomfort, 
restless, seizure and cardiac arrhythmias (Kirsten et al., 1993). Theophylline has 
been used as bronchodilator for several decades, however, it has a narrow 
therapeutic index (10-20 mg/L) (Zhou et al., 2006, Kobayashi et al., 2004, McKay 
et al., 1993). Patients of the oral taking theophylline must therefore have plasma 
concentration monitored (Barnes, 2006).  
Recently, theophylline is marketed under several brand names such as Uniphyl 
and Theochron, which comes as a tablet, capsule, solution, and syrup to take by 
mouth. Its dose is from 80mg to 600mg (DrugBank). Among of them, capsule and 
tablet are extended-release formulation. In clinical studies, they are used as 
bronchodilator in COPD (Barnes, 2003). The mixture of theophylline with 
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ethylenediamine can be given by injection, which is called as aminophylline, but 
this injection is needed rarely for severe asthma.  
1.2.2 Selective beta2 (β2) agonists  
The selective β2 agonists selectively stimulate β2 adrenoceptors in the airway. 
They produce bronchodilation either short or long acting. The short-acting β2 
agonists can immediately relief of asthma symptoms within 5 min by inhalation, 
and is generally at its maximum within 30 min (Rennard, 2004). Salbutamol and 
terbutaline belong to this group. The long-acting β2 agonists, such as formoterol 
and salmeterol, have duration of action, which can be lasted at least 12 h.  
Both short and long acting agonists have inhalation and oral formulations. Inhaled 
medicines can be delivered by pressurized-metered dose inhalators, nebulizer, 
and dry powder inhaler. Particularly, the nebulizer can be used to deliver solutions 
of salbutamol and terbutaline for the treatment of severe acute symptoms.  
The oral preparations of β2 agonists may be beneficial in patients who cannot 
manage the inhaled route, for instance, children and elderly. However the inhaled 
β2 agonists are more effective and less side-effects than oral administration. 
There is a report that have indicated that reduces of oral deposition can be able 
to decrease the systemic effects (Dahl et al., 2001). The side-effects of β2 
agonists include fine tremor, nervous tension, headache, muscle cramps, 
palpitation, and so on (NHS, 2010).   
1.2.3 Anticholinergics bronchodilators 
Anticholinergics also are named as antimuscarinic. They are effective 
bronchodilators because they block the action of acetylcholine on M3 muscarinic 
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receptors that induce contraction on airway smooth muscle (Rennard, 2004). 
Short and long-acting bronchodilators are available.  
Ipratropium can provide short-term relief in COPD, but its action is relatively 
slower than short-acting β2 agonists.  Its maximal effect occurs 30-60 min after 
inhaled and continue the action for 3 to 6 hours. The long-acting anticholinergics 
is tiotropium, which is effective for the management of COPD. It reduces 
exacerbation frequency in COPD patients. Currently, only inhaled 
anticholinergics are used for clinical treatment.  
1.2.4 Corticosteroids 
Corticosteroids (or glucorticosteroids) are widely used in the treatment of 
inflammatory and immune diseases, which have been used for the management 
of reversible and irreversible airway disease. Inhaled steroids have been 
recommended in the BTS guidelines for the prophylaxis of asthma (BTS, 2011). 
In COPD treatment, inhaled corticosteroids also may reduce exacerbations.  
Steroids can be formulated as inhaled, oral and parenteral dosage forms. The 
inhaled steroids could help to distinguish asthma form COPD by using 3-4 weeks 
(BTS, 2011). The combination inhalation therapy (steroids and bronchodilator) 
have been proved to improved forced expiratory volume in 1 second (Cazzola 
and Hanania, 2006). Beclomethasone dipropionate, budesonide, and fluticasone 
propionate have been widely developed for COPD treatment.  
1.3 Inhalation aerosols 
Local delivery of medication to lungs is highly desirable, because of the large 
surface area, the abundance of capillaries and the thinness of the air-blood 
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barrier (Winkler et al., 2004). Therefore, inhaled drugs are delivered to the 
respiratory tract for the treatment of airways diseases, which can result in a rapid 
onset of activity.  Additionally, smaller doses can be administered locally 
compared to delivery by oral or parenteral routes (Sutherland and Cherniack, 
2004), thereby, reducing the potential adverse systemic effects and drug costs. 
Furthermore, the pulmonary route can avoid first-pass metabolism in liver 
(Winkler et al., 2004), as well as issues associated with limited absorption via the 
GI tract and local tolerability issues  Thus this approach has been utilized as a 
portal for entry of peptides and proteins (Hussain et al., 2004).  
1.3.1 Inhalation devices  
Inhaled drug delivery devices are divided into three categories: pressurized 
metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulizers. A 
good delivery device can provide physical and chemical stability of drug 
formulations (Pilcer and Amighi, 2010). Additionally, it can generate a 
homogeneous aerosol and provide reproducible drug dosing. For drug deposition 
purposes, the inhaler should discharge 0.5-5µm particles. Moreover, the ideal 
device must be simple, convenient, inexpensive, and portable.  
 The pMDIs also referred to as metered-dose inhalers (MDIs) are the most 
commonly used inhalation drugs delivery devices (Aulton, 2009). In pMDIs, drug 
is either dissolved or suspended in liquid propellants with other excipients. Upon 
activation, a predetermined volume of liquid (drug and propellant) is released. 
The gas is produced by evaporation of propellants. The propellants used in pMDI 
formulations are liquefied gas, usually chlorofluorocarbons (CFCs) and 
hydrofluoroalkanes (HFAs). The liquefied propellants establish a saturation vapor 
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pressure in the head space of the aerosol canister. On spraying, the propellants 
evaporate, leading to constant and consistent pressure. This high-speed gas flow 
helps to break up the liquid into a fine spray of droplets. Additionally, pMDIs are 
portable, low cost and disposable devices. However, they also demonstrate a 
number of disadvantages. Owning to their high velocity of propellant droplets, 
most of drug is lost through impaction of these droplets in the oropharynx. 
Meanwhile, propellants may not evaporate sufficiently rapidly for droplet size to 
decrease; and the mean droplet size may exceed 40µm which makes it difficult 
for drug to reach the deep lung. An additional problem with pMDIs is their correct 
use by patients. For vital for effective drug deposition and action, that inhalers are 
used in accordance with the manufactures instructions (Crompton, 1982). pMDIs 
should be actuated followed by slow and deep inhalation, followed by a period of 
breath-holding, which is very difficult to control, especially in children and the 
elderly. However, it should be noted that even the correct use of this inhaler, 
pMDIs can result in only 10-20% of the emitted dose being deposited at the site 
of action.  
In DPIs, drug is emitted as a cloud of fine particles. The drugs can be preloaded 
into an inhaler or filled into hard gelatin capsules and foil blister discs (Aulton, 
2009). DPIs have a number of advantages over pMDIs. These advantages are (i) 
delivery of DPI formulations does not rely on propellant, (ii) formulations do not 
contain other excipients except carriers, (iii) usage of DPIs does not require 
inhalation/actuation synchronization, (iv) the normal deep breath can actuate 
DPIs, and result in better lung delivery, (v) DPIs are suitable for delivery of large 
dosages of drugs, and (vi) the volume and concentration of drug is markedly 
restricted by valve in pMDIs. However, there are a number of disadvantages for 
 8 
 
DPIs, for instance, emission of particles from the pMDIs device and 
deaggregation of particles is affected by the patients’ ability to inhale, and DPIs 
are exposed to ambient atmospheric conditions which may reduce formulation 
stability.  
Nebulizers are the first commercial inhaler for inhalation therapy. They have 
subsequently been evolved into three different devices. These include jet 
nebulizers, ultrasonic nebulizers, and vibrating-mesh devices (Aulton, 2009).  
Some studies have indicated that nebulizer always demonstrate low efficient, 
poor reproducibility, and great variability (Pilcer and Amighi, 2010). Nevertheless, 
nebulizers have a number of advantages over pMDIs and DPIs. These are (i) 
nebulizer systems can be used to deliver the formulations which cannot be 
formulated into pMDIs and DPIs, such as large volume solutions and suspensions, 
(ii) nebulizers can emit larger therapeutic doses than pMDIs and DPIs, and (iii) 
drugs can be discharged from nebulizers via normal tidal breathing, thus this kind 
of device is suitable for children, and the elderly.  
1.3.2 Formulation of pulmonary drugs: particle engineering  
Pulmonary deposition performance of the aerosol is predominantly dependent 
upon aerodynamic particle size which is influenced by powder flow, shape, 
surface properties, drug carriers, inhalation devices, and inspiratory flow rate 
(Usmani et al., 2003). Thereby, the balance between inhalation devices, drug 
formulation and patients’ inspiratory flow rate is very important for inhaled drug 
design (Pilcer and Amighi, 2010). To reach this balance, the ideal strategy 
involves particle engineering with the intent to achieve controlled and suitable 
properties such as narrow particle-size distribution and improved dispersibility.  
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The physicochemical characteristics of particles, such as morphology, 
granulometry, stability, can influence dispersive performance of inhaled drugs. 
Particle engineering can control particle size, morphology, and crystal structure 
to meet the requirements of inhaler design and drug delivery. It can narrow the 
particle-size distribution, improve dispersibility, enhance chemical and physical 
stability, and bioavailability. A number of methods have been developed to 
produce particles with desirable characteristics for inhalation. 
1.3.2.1 Milling 
Inhalation products such as pMDIs, suspension nebulizers and DPIs, consist of 
micronized APIs in either agglomerated or blended form. Such particles are 
generally produced by batch crystallization, followed by filtering, drying and 
micronization (Shekunov et al., 2003). Milling is a well-established method for 
particle engineering. It can yield micron size particles for inhaled drugs. One of 
the well-validated methods for manufacture dry powder inhalation is jet mill.  
Jet milling reduces particle size via high velocity particle-particle collision. The 
unmilled particles are fed into milling chamber. The high pressure air from the 
nozzles accelerates the particles. The particles collide and fracture in the 
chamber. Particles are projected around the mill; the larger particles are subject 
to higher centrifugal forces and are therefore forced to the outer perimeter of the 
chamber. The smaller particles drop into the central discharge stream (Aulton, 
2009).  
This technology has been used successfully for producing very fine products. 
However, the fluidized particles may suffer some degree of surface damage, 
leading to generally undesirable breakage (Bentham et al., 2004). Therefore, jet 
 10 
 
milling may be unpredictable to control of important product characteristics such 
as size, shape, morphology, surface properties, and electrostatic charge 
(Bentham et al., 2004, Pilcer and Amighi, 2010). In addition, the jet-milled 
particles have a high interparticle cohesive forces (Fukunaka et al., 2005). This 
micronized powder are grown by the crystals cleave at the cleavage plane, which 
leads to a broad particle size distribution. The micronization method using mills 
is a high-energy input process. It also has been suggested that it could induce 
crystal disorder (Chikhalia et al., 2006) and can enhance chemical degradation 
(Shoyele and Cawthome, 2006). Thus, those milled powders have an unstable 
and controllable physical and chemical properties influence the performance in 
processing and formulations, particularly in DPI delivery. The poor flow properties 
caused by higher energetic surface decrease the delivery efficiency of DPIs. This 
was shown for supercritically produced (volume mean diameter 3.55 µm) and 
milled (1.7 µm) salmeterol xinafoate (Shekunov et al., 2003). However the milled 
sample exhibits a higher bulk density, specific free energy and aerodynamic 
shape factor. The milled particles have a higher tensile strength of the aggregates 
and indicated a two-fold decrease of fine particle fraction deposited in a cascade 
impactor (Shekunov et al., 2003). Milling techniques, in general, show several 
disadvantages, but the advantages of milling include limited metal contamination, 
easy cleaning, simple operation and relativity low cost. However, new techniques 
which produce the drug directly in the required small particle size are desirable, 
and more research is needed.  
Wet milling can achieve nano-size particles (Peltonen and Hirvonen, 2010). 
Micron size drug crystals are media milled in a water-based solution and reduced 
to nanometer-sized particles. This technology has been identified as a useful 
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procedure to develop formulations of poorly-water-soluble compounds. Wet 
milling can be operated in re-circulation mode (Van Eerdenbrugh et al., 2008, 
Peltonen and Hirvonen, 2010). A suspension (Telko and Hickey, 2005) consisting 
of drug, water and excipients is fed into the milling chamber that is charged by 
milling media. In the mill chamber, the suspension is processed into a 
nanocrystalline dispersion. The typical residence time required to generate a 
nanometer-sized dispersion with a mean diameter <200nm is 30-60min.  
During the wet-milling process, the grinding between glass beads and particles 
or particles and particles break up the crystalline lattice for particle size reduction 
(Van Eerdenbrugh et al., 2008). The particle size distribution is related to the 
milling time and size of glass beads (Yang et al., 2008). In Yang’s research, it 
used 0.50–0.75 mm diameters of glass beads and milled for 24 hours to reach a 
crystalline form, potency and homogeneity, and stability nanosuspension of 
budesonide and fluticasone. It should be noted that using glass beads has been 
the possible formation of glass particles from the milling process, which could 
potentially cause lung irritation and influence study results (Yang et al., 2008). In 
nano-crystalline suspensions of naproxen, thermodynamically unstable 
amorphous materials could be created on the surface of particles (Kumar and 
Burgess, 2014). In addition, the presence of aqueous medium could facilitate 
crystalline form conversion or formation of hydrates. The potential solid form 
changes could lead to stability or processing issues for nanosuspensions and 
ultimately impact their performance in lung delivery. 
Wet milling is an advanced technique to generate physically stable dispersions. 
However, this technology may also lead to chemical degradation. It is not suitable 
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for water soluble and the nano-size particles are subject to agglomeration and 
crystal growth.    
1.3.2.2 Spray drying 
Spray drying is a one-step process that converts a liquid feed into a dried particle 
(Aulton, 2009). There are four stages in spray drying: (i) atomization of the feed 
solution, (ii) droplets-air contact, (iii) drying droplet, and (iv) separation of the dried 
particles from the gas stream. The feed solutions can be solution, slurry, 
suspension, and colloidal dispersion.  
The particles produced by spray drying can be manipulated by changing the 
parameters of spray drying (Pilcer and Amighi, 2010, Tong.H. H. Y and Chow.A. 
H. L, 2006, Shoyele, 2008). The design of the nozzle can affect the atomization 
of droplet and control the size of particles. Once the droplets leave the nozzle, 
they make contact with hot gas in the drying chamber. Thus, the inlet and outlet 
temperatures are the most important variables for drying. Additionally, the 
retention time of droplets, drying gas medium, gas humidly, and gas flow rate 
may affect particle shape, size and density. The properties of particles are also 
related to the character of the API solution. The different concentrations, solutes, 
solvents and pH values of solutions can also lead to variations in particle forms.  
There are many COPD medications processing by spray drying, which could be 
injected as solutions, emulsions, and suspensions. In the articles of formulation 
of salbutamol sulfate, the shell-like, ultra-light particles could be generated from 
emulsion (Steckel and Brandes, 2004). If the sample was pre-treated by 
ultrasonic methods, the particles would be needle-like after spray drying (Dhumal 
et al., 2009).  Spraying drying the composite solution of salbutamol sulfate, the 
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obtained particles have a modified surface morphology (Seville et al., 2007). The 
corticosteroid drug, budesonide was spray dried to gain nano-scale particles. 
Nolan et al. (Nolan et al., 2009) found that spray dried budesonide is low density 
and porous-like particle with amorphous content, but the powder is 
thermodynamically stable for up to 12 months.  
Compared to milling, spray drying is easier to generate small spherical particles 
with more homogeneous size distribution (Tong.H. H. Y and Chow.A. H. L, 2006). 
These particles can result in higher respirable fraction than micronized particles 
obtained from mechanical milling. Because spray drying is a fast and high 
temperature process (Shoyele, 2008), the particles generated from solution using 
spray drying are usually amorphous. However, it should be noted that spray 
drying can maintain crystalline state of APIs, when it is drying suspensions and 
slurries.  
1.3.2.3 Spray freeze drying 
Spray freeze drying is a technique to spray drug solution into a vessel filling with 
a cryogenic liquid, such as nitrogen, oxygen, or argon (Aulton, 2009), meanwhile 
the droplets are quickly frozen. Lyophilization of frozen droplets results in porous 
particles suitable for inhalation. Although the porous spherical particles are low 
density, the particles are usually amorphous and high aggregation. Spray freeze 
dried particles can reach to the desired respiratory size range <5 μm or even 
down to nanoscale (Ali and Lamprecht, 2014). Parathyroid hormone particles 
(Shoyele et al., 2011) are spray freeze dried which have mass medium diameter 
12μm and tapped density 0.007 g/cm3. In addition, particles of kanamycin for 
inhalation delivery were produced with the spray freeze-drying method (Her et al., 
 14 
 
2010). The diameters of particles are from 13.5μm to 21.8μm and their 
aerodynamic diameters were between 3.58μm and 6.39μm. Those researches 
suggested that spray freeze drying process delivers very strongly porous 
structures. 
Spray freeze drying is conducted at sub-ambient temperature, thus it can be used 
for processing heat sensitive compounds. It has been widely used in formulation 
of protein and peptide, including anti-IgE monoclonal antibody, 
deoxyribonucleases, insulin, and cetrorelix acetate (Pilcer and Amighi, 2010, 
Sadrzadeh et al., 2007). 
1.3.2.4 Supercritical fluid crystallization 
In recent years, supercritical fluid crystallization (SFC) technologies have gained 
increasing attention in the pharmaceutical industry due to their capability and 
versatility of producing micro-fine particles to predetermined specifications. 
Supercritical fluids (SCFs) technology is a methodology that utilizes carbon 
dioxide (CO2) at temperatures and pressures above its critical point to effuse 
through solids like a gas, and dissolve materials like a liquid, Fig. 1-1.  
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Fig. 1-1. Phase diagram of CO2 
There are three main SCF processes (York P. et al., 2004): (a) precipitation from 
supercritical solutions composed of supercritical fluid and solutions (RESS); (b) 
precipitation from gas saturated solutions (PGSS) and; (c) precipitation from 
saturated solutions using supercritical fluid as anti-solvent (SAS). 
Using RESS drug is firstly dissolved in SCF followed by rapid expansion of the 
fluid solution across a heated orifice to cause a reduction in the density of the 
solution. This leads to a decrease in the solvation power of the fluid which leads 
to precipitation of the drug (York P. et al., 2004). In PGSS, the drug is molten and 
then the SCF is dissolved in the molten solute. The supercritical solution is then 
fed into a chamber via an orifice leading to a rapid expansion under ambient 
condition (Pilcer and Amighi, 2010). However, application of these techniques is 
limited by particle aggregation, nozzle blockage and limited solubility of solutes 
in supercritical CO2 (York P. et al., 2004). Under these circumstances, the third 
method, SAS, becomes the most common method, although a range of different 
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variants have been involved. Each process relies on the capability of SCF to act 
as an anti-solvent (York P. et al., 2004, Pilcer and Amighi, 2010, Tong.H. H. Y 
and Chow.A. H. L, 2006).  CO2 can easily dissolve in organic solvents leading to 
volume expansion. Thereby, when SCF makes contact with drug solutions, it 
results in reduction of solvent density and solvation capability. Such decreases 
lead to increasing levels of supersaturation, solute nucleation and particle 
formation. Finally, the drug particles precipitate during dissolution of SCF into the 
drug solution. Once the solute has precipitated out, the SCF-solvent can be 
removed. However, due to the extremely fast precipitation in SCF, this induces 
amorphicity in same materials (Tong.H. H. Y and Chow.A. H. L, 2006).  
The benefit of SCF technologies is that various particle shapes and morphologies 
can be obtained (compact crystals, needles, dendritic aggregates, balloon-like 
structures, porous aggregates) depending on the controlled supersaturation and 
kinetics of precipitation(York P. et al., 2004). Particles can be produced as single-
components or composites. SCF methods allow designing particle morphology 
and size by several factors: precursor composition and concentration, nozzle 
geometry, spraying distance, operating conditions (T, p, flows, pre-expansion 
pressure)(York P. et al., 2004). Selective precipitation with a control of crystallinity 
and crystalline forms is possible. 
 1.3.2.5 Sonocrystallization  
Ultrasound can affect the nucleation and crystal growth during crystallization 
(Mullin and William J., 2001). The application of ultrasound can induce cavitation 
in the liquid. The cavitation effects produce bubbles (Virone et al., 2006, Narducci 
et al., 2011), which collapse in the liquid. Transient bubble collapse cause local 
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regions of extreme excitation, temperature (5000K) and pressure (2000atm) 
(Keller and Miksis, 1980), and consistent shock waves (Storey and Szeri, 2001). 
These regions lead to an increasing supersaturation, and a decreasing 
temperature of crystallization (Narducci et al., 2011).  
Theoretically, short bursts of ultrasound can produce lower supersaturation and 
continuous sonication would be able to facilitate crystallization at a higher level 
of supersaturation (Ruecroft et al., 2005). In this regard, it is possible to tailor a 
crystal size distribution using different wave frequencies of ultrasound (Kordylla 
et al., 2009). In addition, particle morphology are influenced by ultrasound-
generated temperature and pressure gradients, which reduce particle 
aggregation (Ruecroft et al., 2005). 
Therefore, ultrasound can be able to alter and improve in the physical properties 
associated with solids such as; 
a) Morphologies like particle size, shape, crystal habit, density, porosity etc. 
b) Physical properties which are associated with morphology, such as flowablity, 
compatibility and compressibility. Efficient production of small particles with 
uniform size is required in the pharmaceutical industry due to their impact on 
performance while processing and impact on patients after consumption. 
In recent years, researchers at the University of Bath developed a 
sonocrystallization technology called solution atomization and crystallization by 
sonication (SAX) (Kaerger and Price, 2004), which has been shown to be 
extremely useful in preparation of nano- and micro- size particles. This 
technology consists of four major processes, including (I) formation of API 
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solution, (II) atomization of solution into a chamber, (III) collection of aerosol 
droplet in a nonsolvent, and (IV) application of ultrasound to induce crystallization 
(Ruecroft et al., 2005). SAXS is capable of reproducibly generating particles with 
micro- or nano-size (Bucar and MacGillivray, 2007, Kaerger and Price, 2004) , 
and formation of particles containing multiple drugs (Pitchayajittipong et al., 2009).   
1.5 Combination particles for pulmonary delivery 
Combination particle is a particle containing multiple substances. These particles 
can be imaged to be formed like as in Fig. 1-2. For DPI formulation, it has been 
reported that nanoparticles have been designed to form Trojan, strawberry and 
nanoparticles aggregates (Sofia Silva et al., 2014).  
 
Fig. 1-2. Nanoparticle-based dry powders for inhalation: 1 Trojan particles; 2 
Strawberry particles; 3 Particles with nanofeatures (Sofia Silva et al., 2014) 
Trojan particles are micron-sized large porous particles, which were composed 
by plenty of nano-size particles. The strawberry particle designation first 
appeared during the 2005 Aerosol Society meeting (Sofia Silva et al., 2014), and 
it is associated with micro-carriers coated with active nanoparticles connected. 
This structure is advantageous because it improves flowability and prevents 
aggregation. On the surface, the coated nanoparticles work as spacers between 
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the microparticles, the adhesion between particles is diminished, making the 
handling easier. Moreover, this structure has a potentiality to be used to formulate 
high does DIPs, which can prevent from poor flowability and increase the FPF. 
Finally, particle with nanofeatures is a nano-embedded microparticles. It is a type 
of microcapsules with solid domains. These particles are fabricated from 
macromolecular and/or molecular assemblies, polymers or lipids, in which the 
active principle is either dissolved, entrapped, encapsulated, adsorbed or 
attached to the external interface. 
Combination particles can be formed by different shapes of particles, but the 
spherical particles are the ideal structure for inhalation. Combination particles has 
advantages over a combination product containing both drugs in a physical 
mixture where codeposition of APIs occurs rather randomly when codepositing 
from the same cloud (Westmeier and Steckel, 2008). It is predictable and 
controllable, which can be detected if adhesion of one API over the other on the 
lactose, or along with self-agglomeration of one or both drugs, or will cause 
content segregation, or dose uniformity. All particles have uniform drug 
composition. 
Co-precipitation or co-spray drying a solution containing two APIs is recent 
strategy used to formulate combination particles. Spray drying is a well published 
technology used for formulation of combination particles. In 2006, Corrigan and 
his colleagues (Corrigan et al., 2006) formed salbutamol sulphate/ipratropium 
bromide and salbutamol sulphate/excipient combinations particles by spray 
drying. They reported the fine particle fractions (FPF) of combination particles 
were greater than that of micronized salbutamol sulphate alone. The particles 
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were spherical and diameters range from 1µm to 7µm, which improved their 
flowability and deposition. However, the particles were amorphous, resulting in 
cohesiveness and physically instability. This method was also demonstrated by 
Tajber in 2009 (Tajber et al., 2009a). Tajbar and co-workers formulated 
budesonide/formoterol fumarate particles by spray drying. They also compared 
combination particles with a physical mix of micronized powder in in vitro 
deposition studies (Tajber et al., 2009b), indicating that there was 2.6-fold 
increase in respirable fraction and better dose uniformity. Additionally, drugs 
spray dried with certain excipients can provide crystalline particles. Kumon and 
his co-workers (Kumon et al., 2010) produced a combination particles by spray 
drying solution containing corticosteroids, β2-agonist and mannitol. The particles 
obtained from this solution were crystalline and stable and showed excellent 
aerosol performance.  
Co-precipitation seems a seldom used methodology for producing combination 
particles.  There are a few published papers about this process. Pachuau and his 
co-workers (Pachuau et al., 2008) produced microspheres containing 
theophylline, salbutamol sulphate and polymer via evaporation of emulsions. 
However, the size of microspheres was not suitable for pulmonary delivery. 
Thereby, in order to better control precipitation of particles, there are several 
novel technologies that can potentially be used. Westmeier formulated salmeterol 
xinafoate/fluticasone propionate combination particles using an interdigital slit 
micromixer (MMA, Mainz, Germany) (Westmeier and Steckel, 2008). He firstly 
obtained suspensions from the micromixer; and then spray dried these to obtain 
a dry powder. The shape of particles was needle-like, and thickness of particles 
depended on the solvent composition used. Moreover geometrical dimensions of 
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all particles were less than 10µm. In the aerodynamic assessment, the FPF of 
particles was around 22%. A lactose blend with combined particles resulted in an 
FPF of 36%. Meanwhile, APIs were uniformly distributed throughout the stages 
of the NGI. The other novel formulation used solution atomization and 
crystallization by sonication (SAX), which is developed by University of Bath, UK. 
This technology can be used to form combination particles containing multiple 
substances. So far, they have formulated particles comprising two 
(theophylline/fluticasone propionate (Dhillon A et al.), budesonide/formotrol 
fumarate (Pitchayajittipong C et al.) and fluticasone propionate/salmeterol 
xinafoate (Pitchayajittipong et al., 2009). Three APIs (Dhillon A., 2009) 
(Ipratropium bromide/salmeterol xinafoate/fluticasone propionate and salmeterol 
xinafoate/fluticasone propionate/theophylline) have also been implanted in to dry 
powder aerosols. The volume median diameters of the particles were less than 
5µm. In NGI experiments, the ratio of individual APIs was similar at each stage, 
indicating that combination formulations delivery consistently.  
According to the above described studies, combination particles appear to be an 
ideal formulation method for administering multiple drugs to be delivered in to the 
lung. It has a number of advantages over physical mixtures, for instance, 
combination particles overcome un-evenly delivery caused by physical mixtures, 
leading to better aerodynamic performance and bioavailability. However, 
formation of combination particles is a complicated physical process with high 
energy input. Thereby, it is easy to obtain amorphous particles, which are 
physically unstable. Thus, the selection of process parameters is very important 
to control the physical and chemical characteristics of APIs particles. Therefore, 
in order to obtain consistent deposition of theophylline and corticosteroids in the 
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targeted site of lung, theophylline and corticosteroids can be combined into 
individual particles in accordance with the studies describing in this report.  
1.4 Combination therapy of theophylline with corticosteroids for 
COPD 
Combination inhalation therapy has the potential to provide notable benefits to 
patients through synergistic pharmacological action, resulting in fewer side 
effects, better compliance and improved therapeutic outcomes.  
Since the 1990s, there have been a number of studies investigating combination 
therapies of theophylline and steroids or β2-agnoist for the treatment of COPD 
and asthma. There is known to be limited clinical effect for combination therapy 
using theophylline and β2-agnoist (Cazzola et al., 2000). However, combinations 
of low dose oral-theophylline and low dose inhaled-steroid produced similar 
benefits to monotherapy with high dose steroids in COPD (Van Andel et al., 1999, 
Lim et al., 2000, Evans et al., 1997). 
Thus combination therapy has the potential to provide inexpensive and clinical 
efficient treatment in the patients who are not adequately controlled on steroid 
therapy, whilst avoiding the side effects caused by high theophylline 
concentration. However, some studies have reported no clinical improvements in 
combination therapy in COPD (Van Andel et al., 1999). One explanation could be 
that these patients were treated with inhaled steroid plus oral rather than inhaled 
theophylline, which may cause relatively slower absorption and fewer interactions 
with the inhaled steroid in lung. Therefore, simultaneous inhalation of theophylline 
and steroids may enhance the reproducibility of combination therapy.   
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1.4.1 Combination inhalation in COPD treatment 
Commercially available combination formulations are either mixed solutions or 
blends of the active pharmaceutical ingredients (APIs) with lactose carrier 
particles. Commonly used compound bronchodilator prescribed in COPD are 
combination short-acting β2 agonist and anticholinergic, and combination long-
acting β2 agonist and corticosteroid. The combination short-acting β2 agonist and 
anticholinergic, which is Combivent® (Boehringer Ingelheim). It is a nebulizer 
solution. One spray of Combivent® contains ipratropium and salbutamol. The 
commercial products of combination long-acting β2 agonist and corticosteroid 
include Symbicort® (AstraZeneca) and Seretide® (A & H).  Symbicort® is a 
blended with budesonide and formoterol fumarate. Seretide® contains fluticasone 
propionate and salmeterol.  
Both of formulation are physical mixture of APIs and carriers. In the recent the 
articles, the researchers have found there the deposition of APIs are not 
consistent in NGI from these products. In the aerodynamic properties study of 
Seretide® Accuhaler®, it observed that content of salmeterol was decreased in 
the lower stages. The research of Symbicort® pMDI found significantly differences 
in the stage deposition of budesonide and formoterol fumarate and suggested 
that the two drugs were deposited as separate entities.   
This kind of formulation is made homogeneity depends upon the mixing process. 
However, blending performance is uncontrolled and unpredicted (Kumon et al., 
2010), due to different sizes and amounts of powders and different surface 
energies, leading to API segregation and non-dose-uniformity. Thereby, the 
possible solution is to combine the APIs in one particle, providing differential the 
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advantage over other combination inhalation products produced by physical 
mixing.  
1.6 Aim and scope of the thesis 
Technologies for modifying combination particles in order to achieve a greater 
control of size and surface properties of particles for DPI formulations have been 
investigated for a few years. However, these processes are inefficient to control 
physical and aerodynamic properties of combination particles which contain APIs 
with +20 folds difference. In addition, there is limited researches about 
theophylline DPI and formulation of high dose inhaler.  
The aim of this study is to develop an alternative strategy that is a constructive 
approach for combination particle generation to achieve a successful control of 
the physical characteristics and geometry of active drug materials. 
The scope of this thesis are therefore to:  
1. Produce theophylline particles for use in inhaled formulation by 
micronization processes.  
2. Produce combination particles of theophylline and steroids for inhalation 
purpose by co-spray drying and co-precipitation 
3. Determine the operational parameters of generation process which affect 
the particle size and uniformity of combination particles of theophylline and 
the model drug budesonide.  
4. Investigate the effects on crystallinity and crystal form of particles caused 
by excipients.  
5. Investigate the aerodynamic properties of particles delivered from DPIs.  
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Chapter 2 : Materials and Methodologies  
2.1 Introduction  
In Chapter 1, the importance of the physicochemical properties of components of 
inhalation dosage forms was highlighted. Physicochemical properties such as 
particle size, shape and crystallinity can have a dramatic effect on interparticle 
forces within inhalation dosage forms and drug product performance. This 
chapter, therefore, describes the methodologies of characterisation used in this 
study.  
2.2 Materials  
2.2.1 Active drugs  
Micronized budesonide (JAI RADHE SALES, India), anhydrous theophylline 
(Sigma, UK) were used for this study.  
Steroids are highly effective in reducing inflammation in the airways, however, 
they might be less effective in some patients (Wouters et al., 2005) who have a 
broad spectrum of anti-inflammatory effects in asthma. At a cellular level, 
corticosteroids reduce the number of inflammatory cells in the airways (Barnes, 
1998). They can suppress the production of chemotactic mediators and adhesion 
molecules, leading to inhibition of the recruited inflammatory cells in the airways 
(Barnes, 2005). Due to these reactions of corticosteroids, the inflammatory cells 
such as eosinophils, T lymphocytes, mast cells, and dendritic cells, reduce in the 
airways. 
A previous article reviewed the cellular transportation of corticosteroids (Barnes 
and Adcock, 2003), which indicate the mechanism of transportation. This 
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mechanism is that corticosteroids diffuse across cell membrane by binding to 
glucocorticoid receptors on the cytoplasm. The cytoplasmic glucocorticoid 
receptors are normally bound to proteins, known as molecular chaperone 
proteins. After corticosteroids have bound to glucocorticoid receptors, the 
receptors dissociate with chaperones, leading to the exposure of nuclear 
localization signals on glucocorticoid receptors and translation of the activated 
glucocorticoid receptor-corticosteroid complex into the nucleus. In the nucleus, 
the activated receptor-corticosteroid complex binds to DNA sequence, leading to 
changes in gene transcription, such as increased small number of anti-
inflammatory genes and reduced inflammatory gene expression (Winkler et al., 
2004). For example, the activated receptor-corticosteroid complexes involved in 
histone acetylation (Barnes, 2010, Barnes and Adcock, 2003). Glucocorticoids 
bind to glucocorticoid receptors leading to recruit histone deascetylase 2 
(HDAC2). This suppresses histone acetylation and results in a reduction of 
transcription of genes encoding inflammatory proteins. 
Theophylline has been used for many years, however its molecular mechanisms 
are still uncertain (Ito et al., 2002).  Several molecular mechanisms of action have 
been discussed including inhibition of phosphodiesterases, transcription factor, 
antiapoptotic protein, and adenosine receptor antagonism, and stimulation of IL-
10 and HDACs, but among of them, most seem to occur with higher 
concentrations than those recommended for the clinical situation.  
According to recent articles, theophylline provides anti-inflammatory effects 
within its therapeutically relevant concentration (Barnes, 2006, Kobayashi et al., 
2004). The anti-inflammatory mechanism of theophylline has been described in 
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terms of histone deascetylase (HDACs) activation (Ito et al., 2002). HDACs which 
is related to inflammatory gene transcription (Barnes et al., 2005) and is usually 
decreased in COPD (Ito et al., 2005). This reduction of HDACs leads to an 
increase of inflammatory gene expression. The anti-inflammatory mechanism of 
theophylline in COPD appears to directly activate HDACs to suppress 
inflammatory gene transcription by using low dose of theophylline (about 5 mg/L) 
(Ito et al., 2002, Hansel et al., 2004, Cosio et al., 2004). This interaction occurs 
at therapeutic concentration of theophylline (2 mg/L-2 mg/L), and is diminished 
at higher concentration (20 mg/L), which suggests that using low dosage of 
theophylline as anti-inflammatory substance will benefit the COPD, minimize the 
side effects caused by high dose and will also potentially avoid the requirement 
to monitor plasma concentration very closely (Rossi et al., 2002).  
Mechanism of corticosteroid has been well explained in (Barnes and Adcock, 
2003). Interestingly, it was found that steroids activate HDACs activity by 
recruitment of HDACs to activated transcription site. However, in the patients with 
COPD, there is an extreme reduction of HDAC activity and HDAC2 expression 
(Ito et al., 2005), which is the main cause of steroid resistance. On the other hand, 
the effect of theophylline is different from that of corticosteroids. It appears that 
theophylline is related directly to the activation of HDACs and switches 
inflammatory gene transcription (Ito et al., 2002). This reaction independent of 
the level of HDACs can be detected at the low levels of these enzymes. In this 
regard, theophylline can enhance HDAC activity in COPD patients. Combination 
therapy with theophylline and corticosteroids may therefore be able to enhance 
the efficiency of corticosteroids and recover their anti-inflammatory actions in 
COPD treatment (Lim et al., 2000, Spears et al., 2009, Ford et al., 2010). 
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2.2.2 Excipients  
2.2.2.1 Lactose  
Lactose ML001 (Respitose® ML001, DFE Pharma, Germany) was used as carrier. 
Lactose is by far the most important carrier used for inhalants (Pilcer and Amighi, 
2010). It is one of the very few substances accepted by all medical and regulatory 
authorities as being ideal for inhaled medicines. Every type of inhaler requires a 
different grade and blend of lactose to ensure the best possible performance. 
Therefore, the various grade of lactose were used for aerosolization performance 
study to select the desired grade of carrier. The results of this experiment were 
illustrated in Appendix’s Figure A1. With regard to this study, ML001 (Respitose® 
ML001, DFE Pharma, Germany) was selected in which particle size distribution 
was indicated in Table 2-1.  
Table 2-1 Particle size distribution of Respitose® ML001 (cited from DFE 
Pharma product certificate) 
 Typical (µm) 
d10 4  
d50 55 
d90 170 
 Specification  Typical  
<45µm 40-60% 45% 
<100µm 75-100% 82% 
<150µm 90-100% 96% 
<315µm 99.5-100% 100% 
 
 
2.2.2.2 Polymers 
Polymers applied in this study were used to inhibit crystal growth (Xia et al., 2012), 
improve the structure of particles (Singh et al., 2010) and stabilize uniformity of 
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nanosuspension (Verma et al., 2009). Due to the sensitivity of lung tissue, a limit 
number of excipients are currently approved by the Food and Drug Administration 
(FDA) for inhalation. Among them, the safe polymeric excipients are 
polyvinylpyrrolidone(PVP), polyvinyl alcohol(PVA), hydroxypropyl methyl 
cellulose(HPMC), hydroxypropylcellulose(HPC), chitosan, cyclodextrins, 
hyaluronan, and polymeric surfactant (Tween 20 and Tween 80) (Dumitriu and 
Popa, 2013).  
In order to obtain particles with inhalable size range and controllable morphology, 
HPMC can directly inhibit crystal growth and control particle size in antisolvent 
precipitation procedure (Smyth and Hickey, 2011). Along with PVP, HPMC–PVP 
interactions accumulate at the boundary layer around the drug particles thus 
leading to growth inhibition and additional prolonged stability (Ali et al., 2009). In 
nano-suspension, the neutral HPMC and PVP were used, because their 
stabilizing ability is less dependent than ionic polymers or surfactants, which are 
upon changes in the chemical environment, such as changes in pH (Sepassi et 
al., 2007). Moreover, a published work has demonstrated that HPMC miscible 
with PVP enhanced the mucoadhesive properties of copolymer (Karavas et al., 
2006) that improve the ability to trap nanoparticles of active drugs.  
In this study, Polyvinylpyrrolidone PVP (Kollidon 25, BASF, Ludwigshafen, 
Germany), hydroxypropylmethyl cellulose (HPMC, Metolose 60 SH 50, Shin-
EtsuChemical,Tokyo, Japan) were employed.  
2.2.3 Chemicals for inverse gas chromatography (IGC) 
Probes used for IGC including non-polar and polar probes.   
The non-polar probes used (n-alkanes) in ICG for this project are listed as below: 
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(i) Hexane, 95% HPLC grade, Batch No.-1072208, Fisher scientific, England 
(ii) Heptane, 99+% purity, Lot No.-50228042, Sigma-Aldrich, Gillingham, 
England 
(iii) Octane, 99+% purity, Lot No.-CO04654BO, Aldrich Chemical Company, 
W1, USA 
(iv) Nonane, 99+% purity, Lot No.-EO08280AO, Aldrich Chemical Company, 
W1, USA 
The polar probes used in inverse gas chromatography (GC) for this project are 
given as follows: 
(i) Chloroform, HPLC grade, Batch No.-0565673, Fisher scientific, England 
(ii) Acetone, 99+%, Lot No.-9307A, Sigma-Aldrich, England 
(iii) Ethylacetate, 99+% purity, HPLC grade, Sigma-Aldrich, England 
(iv) Tetrahydrofuran, 99+% purity, Lot No.-13540, Rathburn Chemical Ltd., 
Scotland 
The Materials were used for IGC column preparation are those in the following 
items: 
(i) Glass columns, 1.27m length (1.5 loops), 3mm i.d., 6mm o.d., Glass 
blowing workshop, University of Bradford, UK. 
(ii) Glass column, 0.68m length (single U shape), 3mm i.d., 6mm o.d., 
Glass blowing workshop, University of Bradford, UK. 
(iii) Methanol, 99+% purity, HPLC grad, Batch No.- 092356 
(iv) Tolune, 99+% purity, Laboratory grad, Bach No.- 0814374   
(v) Dimethylchlorosilane, Lot No.-55H1218, Aldrich, England 
(vi) Silanised glass wool, Lot No.-592, Jones Chromatography, Scotland 
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Moreover, the compressed gasses also used for IGC analysis. These gasses are 
hydrogen, nitrogen and air, and all from BOC Ltd., England.  
2.3 Particle engineering  
2.3.1 Jet milling 
The FPS spiral fluid jet mill was used to reduce the particle size distribution of 
theophylline. The particle size can be controlled through changing the feed rate 
alongside with grinding and injection pressures. In this study, the grinding 
pressure and injection pressure were set 5 bar and 8 bar, respectively. 
Theophylline was loaded into grinding chamber at speed of 231 mg/ml. 
2.3.2 Spray drying 
The samples was spray dried from a saturated solution using a LU – 228 
ADVANCED Spray Dryer (Labultima, Maharashtra, India) fitted with a standard 
FLU-P-4.01 spray nozzle. Because there an article has proved that process 
temperatures did not have significant effects on physical properties of particles 
(Nandiyanto and Okuyama, 2011, Tong.H. H. Y and Chow.A. H. L, 2006, Asada 
et al., 2004), in this study, the atomising air pressure at which the spray dryer 
operated was set to 2 Kg/cm2. The process parameters are given as follows: (1) 
inlet temperature: 75-80 ◦C; (2) airflow rate: 60 Nm3/h; (3) feed pump flow rate: 
2ml/min. These parameters resulted in the outlet temperature of 37-40 ◦C. The 
processed solutions were prepared by ultrasonication at room temperature (20 
◦C), in which the solvent contains 80% (v/v) ethanol and 20% (v/v) deionised 
water, and the concentration of APIs at about 2.9% W/V. The solutions were 
prepared with and without polymers.   
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2.3.3 Wet milling 
The wet mill has the ability to reduce the particle size distribution to submicron 
size. In this study, the impacts on wet milling on the size of theophylline particles 
was assessed using only distilled water in the absence of stabilizer. The basic 
operation is described as follows: 
Firstly, theophylline was dispersed in distilled water to produce a 10% 
theophylline suspension. Following this, 250ml of homogenized suspension was 
poured into sample holder and then fed into milling chamber. After that, the bulk 
populations of the nanosuspension were analysed by photon correlation 
spectroscopy. Finally, samples of suspension were analysed at 5, 15, 30, 45, 60, 
and 75 minutes. The suspension obtained at 45 minutes was used as final sample 
of wet milling and for the characterization of particle properties. 
2.3.4 Ultrasonic production  
The ultrasound equipment consists of a probe and high intensity ultrasonic 
processor/sonifier (Sonics and Materials Inc., Vibra Cell, Model VCX 500, 
Connecticut, USA) with temperature controller microprocessor. A high intensity 
solid probe (tip diameter 13mm) was immersed (tip 5 mm in process liquid in a 
jacketed flow cell) in the processing liquid(Muhammad et al., 2013). The device 
was operated at a fixed wavelength of 20 kHz and capable of producing a 
maximum power output of 500 W. 
2.4 Particle characterisation  
2.4.1 Determination of particle size distribution  
2.4.1.1 Laser diffraction 
The particles size distribution of samples were analysed using laser diffraction. 
The technique of laser diffraction is based around the principle that particles 
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passing through a laser beam which scatters light at an angle that is directly 
related to their size. As the particle size decreases, the observed scattering angle 
increases logarithmically. In this study, micro-particle sizing was carried out by 
laser diffraction through using Malvern Mastersizer Sirocco 2000 (Malvern 
Instruments Ltd., UK).  
2.4.1.1.1 Analysis of raw materials  
Measurements of particle size distributions of particle were obtained by using a 
laser diffraction particle sizer HELOS (Sympatec GmbH, System-Partikel-
Technik, Germany). For each batch, the measurement was conducted and 
repeated in triplicate time adopting three individual samples. 
Table 2-2 is the inspection of the particle size distribution of the raw materials, 
which shows the cumulative distribution of raw theophylline (TH00) and 
budesonide (BU00).  
Table 2-2 Summary particle size statistics of the raw drugs  
Samples Particle Size Distribution  
D10 (µm) 
(±SD) 
D50 (µm) 
(±SD) 
D90 (µm) 
(±SD) 
TH00 11.18 (0.2) 27.74 (2.4) 67.85 (7.12) 
BU00 0.57 (0.04) 1.38 (0.01) 0.04) 
 
 
2.4.1.2 Dynamic light scattering 
The Zetasizer Nano uses dynamic light scattering. Dynamic light scattering is 
based on Brownian motion of molecules or particles in suspension, which is the 
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motion induced by the bombardment from solvent molecules. The particles or 
molecules in suspension are illuminated with a laser which changes the intensity 
of the scattered light fluctuates. This change dependent upon the size of the 
particles as smaller particles create more fluctuations (Sartor). It is possible to 
compute the particle size distribution and give a description of the particle’s 
motion in the medium, and measuring the diffusion coefficient of the particle. 
2.4.1.2.1 Analysis of wet milling theophylline  
The theophylline nanoscale suspension was evaluated using Zetasizer Nano 
(Malvern Instruments Ltd) to determine particle size distribution of theophylline 
suspension that was made by wet milling. Table 2-3 illustrate the average 
particles size of theophylline suspension at different time points. 
Table 2-3 the average particles size of theophylline submicron suspension 
produced by wet milling (none stabilizer)  
Time Point  
(minutes)  
Particle diameter 
(nm) 
Width of Size distribution 
(nm) 
5 310.4 71.67 
15 359.7 76.40 
45 383.7 86.21 
60 588.6 118.8 
75 757.1 256.9 
 
2.4.2 Power x-ray diffraction (PXDR) 
PXDR is an application to detect the changes in the intensity of reflected beams 
relating to the crystal structure of samples. It works on the principle of keeping 
the wavelength constant and varying the angle of incidence, θ towards to the 
samples. The reflections of incidences obey the Bragg equation (Equation 2-1)(C. 
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Suryanarayana and Norton, 1998). The resultant diffracted X-Rays are detected 
and processed producing a diffraction pattern.  
nλ = 2dhkI sin θ                                     (Equation 2-1) 
where n is the order of diffraction, λ is the wavelength, dhkI is the space between 
two lattice planes and θ is the angle of incidence ( and reflection) of beam to the 
planes.  
In this work, powder XRD analysis was conducted using nickel filtered Cu Kα, 
λ=1.542Å monochromatic radiation on a Bruker D-8 powder x-ray diffractometer 
(Bruker, Kahlsruhl, Germany). The anode X-ray tube was operated at 40 kV and 
30mA. Measurements were taken at 2θ=5◦-35◦ at a step size of 2θ=1◦ per min. 
Low background silicon mounts (Bruker AXS, UK) were used to support the 
sample during measurements. 
2.4.2.1 Analysis of raw materials  
The raw APIs were analysed by XRD to discover if there contained any 
amorphous content. As shown in Fig. 2-1, the samples were highly crystalline. 
The observed diffraction patterns are in accordance with published articles 
(Toropainen et al., 2006, Otsuka and Kinoshita, 2010), which demonstrate that 
the raw materials comply with the expected crystalline structures.  
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B 
 
Fig. 2-1. XRPD patterns: A. Budesonide BU00; B. Theophylline TH00 
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2.4.3 Thermal gravimetric analysis (TGA) and differential scanning calorimetry 
(DSC) 
Thermal gravimetric analysis (TGA) is used to measure the changes in weight of 
a sample in relation to the change in temperature. The weight changes of 
theophylline or budesonide associated with the decomposition or desorption is 
detected using a high precision electronic microbalance in the TGA.  
Differential scanning calorimetry (DSC) thermograms were obtained using the TA 
instruments Q2000. It was used to detect the changes in heat flow between the 
sample and a reference, which is related to physical transformation, such as 
material melting, glass transition and fusion. Each of these parameters can be 
used to make an assessment of the degree of crystallinity or physical properties 
of polymer or hydrate of a sample.    
Differential scanning calorimetry (DSC) experiments were conducted using TA 
instruments Q2000 (TA Instruments, UK). Hermetically sealed aluminium pans 
were used throughout the study. Moreover, Thermogravimetric Analysis (TGA) 
was performed using TA instrument Q5000 (TA Instruments, West Sussex, UK). 
It should be noted that a heating rate of 10 ◦C/min was set in all DSC and TGA 
measurements. 
2.4.3.1 Analysis of raw materials  
The result of thermal analysis for TH00 and BU00 are displayed in Fig. 2-2. 
According to the result, TH00 is stable up to approximately 200 ◦C and then loss 
weight dramatically. As for the BU00, it was found that it decompose at a 
temperature of approximately 280 ◦C. DSC confirms that both raw materials are 
crystalline with melting points of 260 ◦C and 270 ◦C, respectively. 
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A 
 
B 
 
Fig. 2-2. Figure of thermal analysis for raw theophylline (TH00) and raw 
budesonide (BU00). A: TGA plots for TH00 and BU00; B: DCS plots for TH00 
and BU00. 
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2.4.4 Scanning electron microscopy (SEM) 
Scanning electron microscopy (SEM) is a type of electron microscope, which 
consists of a tungsten cathode, which emits a high energy electron beam. The 
electron beam is then accelerated towards an anode, and focused by condenser 
lenses. The focused electron beam is deflected horizontally and vertically by a 
pair of scanning coils. The electron beam exchanges the energy with the sample 
and emits the electrons and electromagnetic radiation, which are ultimately 
detected and imaged.  
SEM analysis was performed using a Quanta 400 SEM (FEI Company, UK) 
variable pressure scanning electron microscope. Samples were glued onto 
aluminium stubs and sputter coated with gold prior to analysis. 
2.4.4.1 Analysis of raw materials  
All materials were analysed by SEM at a range of magnifications. The obtained 
images are shown in Fig. 2-3. As illustrated in Fig. 2-3, the size of TH00 is over 
ten times larger than BU00. The raw theophylline is needle-like shape with the 
particle size more than 50µm. In the Fig. 2-3-B, particle size of BU00 is about 
5µm and particles bind together. 
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B 
 
Fig. 2-3. SEM of raw materials. A=TH00 x500, B=BU00 x8000 
 
2.4.5 Dynamic vapour sorption (DVS) 
Dynamic vapour sorption is a technique to measure changes in the mass of a 
sample at different relative humidities (RH). It is able to detect amorphous content 
down to a level of 0.5%.   
The weight change of sample associated with the water vapour sorption and 
desorption was monitored using an IGAsorp moisture sorption analyser (Hiden 
Analyticals, UK). Each sample was loaded in a meshed sample basket and 
exposed to dry air until a constant weight was obtained. The relative humidity was 
then increased from 0% to 95% in 10% increments per step. Thereafter, the 
sample was exposed to RH of 95%. The humidity was then reduced in a stepwise 
down to 0%. All experiments were run at 25 ◦C (room temperature).  
The result of DVS is illustrated in Appendix’s Figure A2.  
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2.4.6 Inverse gas chromatography (IGC) 
Inverse gas chromatography is a technique employed to detect the surface free 
energy of an unknown solid using a number of volatile probes. These probes 
include polar and non-polar probes, which bind to the surface of the sample and 
are eluted using nitrogen. Its retention time and volume can be detected via flame 
ionization detector(Buckton and Gill, 2007).  The retention time and volumes then 
are utilised to calculate the surface free energy and specific energy, which 
influence moisture adsorption and desorption, wetting, dissolution, gas 
absorption, cohesion and adhesion. The dispersive component of the solid 
surface free energy (γs
d ) is calculated by following relationships (Equation 2-2) 
(Gamble et al., 2011): 
𝑅𝑇 𝑙𝑛𝑉𝑁 = 2𝑁√𝛾𝑠
𝑑𝑎√𝛾1
𝑑 + 𝑐                        (Equation 2-2) 
Where R is the gas constant, T is the temperature, N is the Avogadro’s number, 
α is the projected surface are of the sample probe, γ1
dis the dispersive component 
of the probe, and VN is the net volume of carrier gas. The surface free energy is 
determined from the slop of retention volume (RT lnVn) against a(γ1
d)0.5. 
In the experiment, IGC was run on a Hewlett Packard 5710A gas chromatograph. 
Nitrogen was used as the carrier gas while Air and hydrogen was adopted to 
enable the flame ionization detector at flow rate of 240 and 30 cm3 min-1. The 
temperature of the injection port and the detector were set at 100 and 150 ◦C 
respectively.  The injection volume was set at 0 ml to satisfy the requirement of 
infinite dilution and speed was set to NORM. The sample was loaded into a pre-
silanised glass column which was deactivated by methanol, toluene and 5% 
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deimethychlorosilane and then the end of the column plugged with silanised glass 
wool. 
2.4.6.1 Analysis of raw materials  
The IGC analysis was carried out on samples of TH00 and BU00. The results 
from the analysed data shows that TH00 has similar dispersive energy to 
budesonide, which is (45.8±1.9 mJ/m2) and (45±0.1 mJ/m2) respectively. Also as 
can be noticed in Fig. 2-4, THF and ethyl acetate probes have a greater affinity 
for the TH than BU. These results suggest that acidic domains are exposed in 
theophylline rather than in budesonide. TH00 is considered to be more polar than 
BU00. This could be able to explain why theophylline has higher solubility in water 
than budesonide. 
 
Fig. 2-4. Specific surface energies obtained for the TH00 and BU00. Energy 
values are in mJ/m2.  The number in graph is average result with error bars 
denoting SD. 
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2.4.7 Characterization of aerosols 
Deposition of aerosols within the respiratory tract is dependent upon inertial 
impaction, gravitational sedimentation and Brownian diffusion (Yeh et al., 1976). 
Therefore, particle size, morphology and surface properties have the potential to 
affect pulmonary performances of aerosols. Among these parameters, particle 
size is an important factor in determining aerosol deposition and also in aerosol 
formulation. 
2.4.7.1 Particle diameter  
Drug particles in an aerosol are normally characterized for size using the 
parameter aerodynamic diameter (dae). The aerodynamic diameter is the 
diameter of a sphere with a unit density that has the same terminal settling 
velocity in still air as the particle in consideration (de Boer et al., 2002). It is 
measured by sizing techniques that are based on inertial impaction. The 
aerodynamic diameter (dae) is defined by the Equation 2-3 (de Boer et al., 2002, 
Hinds, 1982): 
𝑑𝑎𝑒 = 𝑑𝑔𝑒𝑜√
𝜌𝑝
𝜌𝑜𝜒
                                 (Equation 2-3) 
(dgeo: geometric diameter, ρp: particle density, ρo: unit densities, χ: dynamic 
shape factor) 
Owing to this equation is generated by determination of sedimentation velocity of 
particles with unit shape, therefore, this equation is not suitable for the particle 
that varies across a size distribution. A descriptor of the particle size distribution 
is mass median aerodynamic diameter (MMAD) (Usmani et al., 2003). MMAD is 
a calculated aerodynamic diameter that is particle size distribution of half mass 
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of particles, and is a term along with the geometric standard deviation (GSD) to 
describe an aerosol. GSD is a parameter of polydispersity of an aerosol. It should 
be mentioned that Monodisperse and heterodisperse aerosols have a  GSD of 1 
and greater than 1.2  respectively (Musante et al., 2002).  
For pulmonary drug delivery, the optimum particle size is required between 0.5 
and 5µm to reach the lower respiratory tract for optimal pulmonary drug 
deposition. If the size of particles is outside of this range, it would either deposit 
in the oropharynx or be subject to exhaustion (Byron, 1986, Moren, 1987, Zanen 
et al., 1996).  
2.4.7.2 In vitro assessment  
In vitro methods are used to assess the uniformity of dose and particle size 
distribution of an aerosol. The main method of in vitro assessment is by inertial 
impaction.  Inertial impaction is a precise and sensitive technique able to predict 
pulmonary performance of an aerosol. Currently the BP (2014) recommends the 
use of Apparatus A (glass impinger), Apparatus C (multi-stage liquid impinger) 
Apparatus D (Andersen cascade impactor) and Apparatus E (next generation 
impactor) for the sizing of aerosols (Agency, 2014).   
2.4.7.2.1 Glass impinger (Twin stage impinger)  
Fig. 2-5 illustrates a typical twin stage impinge (Agency, 2014). As can be seen, 
the glass impinger consists of two chambers, i.e. upper and lower. An aerosol is 
discharged from mouthpiece adaptor, and is fractionated according to particle 
size. The larger size would hypothetically impact in the upper respiratory tract. 
This fraction size would deposit in upper chamber. The respirable fraction should 
penetrate into lower chamber. This process is typically undertaken at operational 
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flow rate of 60±5 litres/min. The cut point of first stage is greater than 6.4µm and 
the second stage is less than 6.4µm. This leads to the glass impinger is not 
precise as other multi-stages impinger. However, for the sake of simplicity and 
time saving in the analysis, it is therefore usually adopted for routine quality 
assessment. 
 
 
 
Fig. 2-5. Apparatus of twin impinger is described by British Pharmacopeia 
2014(Agency, 2014) 
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2.4.7.2.2 Multi-stage liquid impinger 
A multi-stage liquid impinger (MSLI) consists of impaction stage 1 (pre-separator), 
2, 3, and 4 and integral filter stage (stage 5), which can be shown in Fig. 2-6. As 
can be noticed, the cut-off diameter of each stage is 25, 13, 6.8, 3.1 and 1.7µm 
respectively. The outlet of impinger connects to a suitable vacuum pump, from 
which the flow rate of inlet is adjusted to 30 litres/min (±5 per cent). The MSLI has 
several advantages over the glass impinger in that the former device can classify 
the size distribution to greater degree. Further, the MSLI is calibrated to measure 
the particle size of an aerosol at flow rates ranging from 30 to 100 L/min.  
 
 
Fig. 2-6. Apparatus of MSLI is described by British Pharmacopeia 2014 (Agency, 
2014) 
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2.4.7.2.3 Andersen cascade impactor 
Fig. 2-7 describes an Andersen cascade impactor (ACI) which has been widely 
used in pharmaceutical aerosol characterization. It is designed to cover the size 
range of importance in pulmonary deposition. The ACI consists of eight stages 
together with a final filter. The diameter of the aperture on each stage decreases 
progressively. Impactor is measurements are conducted at flow rate of 28.3 
litres/min; and the particles deposit on eight stages with different cut-off diameters 
of 9, 5.8, 4.7, 3.3, 2.1, 1.1, 0.7, and 0.4 respectively. The ACI is superior to both 
the twin impinger and MSLI in that the ACI can produce more detailed particle 
size distribution of the aerosolized drug. However, it still has some limitations 
including collection surface, overloading of collected particle deposits, and inter-
stage loss.  
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Fig. 2-7. Apparatus of ACI is described by British Pharmacopeia 2014(Agency, 
2014) 
 2.4.7.2.4 Next generation impactor (NGI) 
The next generation impactor (NGI) is a seven stage cascade impactor, as 
depicted in Fig.2-8. It can be operated at flow rate range of 30 litres/min to 100 
litres/min. The 50 percent-efficiency cut-off diameter is from 11.7 to 0.24 µm. 
Within this flow range, there are usually at least 5 stages with D50 values 
between 0.5 µm and 6.5 µm. The NGI is 50% more productive than the ACI, 
because a clean induction port/preseparator and set of cups can be inserted for 
a new test while samples from a previous test are processed. With semi-
automated sample analysis provided by adjunct instruments, the NGI can handle 
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as many as 30 tests per day compared to the typical manual rate for an ACI of 5 
per day (Copley). 
 
 
Fig. 2-8.  Apparatus of NGI is described by British Pharmacopeia 2014(Agency, 
2014) 
For assessment of the aerodynamic behaviour of the particles, the powder had 
to be dispersed into an air stream. In this assessment, the Aeroliser® device was 
used to test the aerosolisation of the dry powders. 
The aerodynamic behaviour of the particles was assessed using a Next 
Generation Impactor (NGI, Copley Scientific Limited, Nottingham, UK) at a flow 
rate of 60 L/min, which corresponds to a run time of 4s for an inspiration flow of 
4L (Agency, 2014). The powder was directly weighed into HPMC capsule (Size 
3, CAPSUGEL, Germany) or an interactive mixture of particles with lactose 
(Respitose® ML001, DFE Pharma, Germany) as carrier was made and 
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subsequently weighed into capsules. In order to obtain a good quality lactose-
APIs mixture and physical mixture of APIs sandwich- method was used. 
Theophylline:budesonide were mixed at ratio of 20 to 1. The filled capsules were 
stored dry until used and then individually placed in the Aeroliser® device. If the 
capsule was not emptied at the first discharge, a second actuation followed as 
described in the user instructions of the Aeroliser® device. 
All capsules were collected after emptying and washed with 80% methanol to 
determine the amount of APIs. All NGI stages as well as the throat and the 
preseparator were washed with 80% methanol to dissolve the drug on the stages 
for HPLC analysis. All measurements were performed in triplicate. FPF was 
calculated as the percentage of drug particles below a size of 5μm. When the 
flow rate is 60 L/min, stage 4 until the MOC were utilised. 
2.4.8 Drug quantification 
Determination of drug content and analysis of NGI measurements was carried 
out using HPLC (Waters Corp., USA). A 5 μm Nucleosil C18 column (SUPELCO 
INC. USA) with Nucleosil® Guard Column (SUPELCO INC. USA) was used as 
stationary phase, which was conditioned to 37 ◦C in a column oven. As mobile 
phase a mixture of methanol and water (80:20) was used. Flow rate was 1 mL/min; 
detection wavelength was 270 nm for theophylline (tr for theophylline 2.8 min). 
The wavelength of 244 nm was used to detect budesonide (tr for budesonide 3.8 
min).Quantification was carried out by an external standard method. 
2.5 Statistic analysis  
2.5.1 Design of experiments (DOE) 
Design of experiments (DOE) is the design of any information-gathering 
exercises where variation is present (JMP, Barrentine, 1999). DOE can identify 
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important interactions that may be missed when experimenting with one factor at 
a time to determine whether the experiments are under the full control or not. It 
is also a process to organize the experiment properly to ensure that the amount 
of reliable data is available to answer the questions of interest as clear and 
efficient as possible.  
On the other hand, DOE is the simultaneous study of several process variables. 
By combining several variables in one study instead of creating separate study 
for each, the amount of testing required will be drastically reduced and greater 
process understanding (Barrentine, 1999) can be attained. The objectives of the 
DOE here are:  
1. To understand how to change a process average in desired direction 
2. To learn how to reduce process variation 
3. To learn how to make response controllable 
4. To identify which variables are important or not  
Before experimentation, a hypothesis should be made and terminology should be 
defined (Barrentine, 1999). According to literature (Barrentine, 1999), the 
following actions should be considered for better managing of an experiment. 
1. Define the process to be studies  
2. Determine the responses  
3. Determine the measurement precision and accuracy 
4. Generate candidate factors  
5. Determine level of factors 
6. Select the experimental design  
7. Have a plan to control extraneous variables 
 52 
 
8. Perform the experiments according to the design  
9. Analyse and draw conclusions 
10. Verify and documents the new process  
11. Propose the next study  
The screening design, full factorial deign and fractional factorial design have 
become popular in industry and academic research over the last decade. 
Screening design is typically used in the initial stages of experimentation. They 
examine many factors to identify those that have the greatest effect on the 
response or responses. The identified factors are then studied using more 
sensitive designs. This experimental design is popular for 2 or more factors with 
two-level (JMP) 
A full factorial design contains all possible combinations of a set of factors. This 
is the most fool proof design approach, but it is also the most costly in 
experimental resources. Thereby, full factorial design is suitable for small data 
set. In full factorial designs, experiments run at every combination of the factor 
levels. The sample size is the product of the numbers of levels of the factors. For 
example, a factorial experiment with a two-level factor, a three-level factor, has 2 
x 3 = 6 runs (JMP). 
If full factorial design is too high to be logistically feasible, a fractional factorial 
design may be done, in which some of the possible combinations are 
meaningless. In statistics, fractional factorial designs are experimental designs 
consisting of a carefully chosen fraction of the experimental runs of a full factorial 
design (Wikipedia, 2012). The fraction is chosen experiments which are the most 
important features of the problem studies, while using a fraction of the effort of a 
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full factorial design in terms of experimental runs and resources. An important 
property of a fractional design is its resolution to separate main effects and low-
order interactions from one another. There are six types of resolution. Among 
them, Resolution III, IV and V are important and common designs (SUPPORT). 
The resolution III is used for the situation, which no main effects are aliased with 
any other main effect, but main effects are aliased with 2-factor interactions. 
Example can be given as: 23 − 1 with defining relation I = ABC. As for Resolution 
IV, it can resolute the factors, in which no main effects are aliased with any other 
main effect or 2-factor interactions, but some 2-factor interactions are aliased with 
other 2-factor interactions and main effects are aliased with 3-factor interactions. 
Example can be shown as: 24 − 1 with defining relation I = ABCD.  Resolution V is 
suitable for the factors, which do not have main effects or 2-factor interactions 
are aliased with any other main effect or 2-factor interactions, but 2-factor 
interactions are aliased with 3-factor interactions and main effects are aliased 
with 4-factor interactions. Example can be elucidated as: 25 − 1 with defining 
relation I = ABCDE. 
2.5.2 Regression analysis  
In statistics, regression analysis is a statistical process for estimating the 
relationships among variables. It includes many techniques for modelling and 
analysing several variables, when the focus is on the relationship between a 
dependent variable and one or more independent variables. More specifically, 
regression analysis helps one understand how the typical value of the dependent 
variable changes when any one of the independent variables is varied, while the 
other independent variables are held fixed. Most commonly, regression analysis 
estimates the conditional expectation of the dependent variable given the 
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independent variables. That is the average value of the dependent variable when 
the independent variables are fixed. Less commonly, the focus is on a quantile, 
or other location parameter of the conditional distribution of the dependent 
variable given the independent variables. In all cases, the estimation target is a 
function of the independent variables called the regression function. In regression 
analysis, it is also of interest to characterize the variation of the dependent 
variable around the regression function which can be described by a probability 
distribution. 
Regression model describes relationship between a scalar dependent variable 
and one or more explanatory variables. It is a method of analysis for assessing 
the coefficients between a set of independent variables and dependent variable. 
Applying regression analysis to a set of data results in what are known as 
regression coefficients, one for each explanatory variable. Therefore, the 
regression model is useful for a response variable with observed values.  
The mathematical expression for regression model can be described as below:  
                Y = β0 + β1x1 + β2x2 … + βpxp + ϵ                               (Equation 2-4) 
The regression coefficients, β0, β1…βp are generally estimated by least squares. 
The fit of a regression model can be judged with calculation of the correlation 
coefficient, R2, defined as the correlation between the observed values of the 
response variable and the values predicted by the model (Paul R. Kinnear and 
Gray., 2008). This model was generated using SPSS software (IBM SPSS 
statistics 19, USA).  
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Analysis of variance (ANOVA) is a collection of statistical models used to analyse 
the differences between group means and their associated procedures, such as 
"variation" among and between groups (Julie, 2013). In the ANOVA setting, the 
observed variance in a particular variable is partitioned into components 
attributable to different sources of variation. In its simplest form, ANOVA provides 
a statistical test of whether or not the means of several groups are equal, and 
therefore generalizes the t-test to more than two groups. As doing multiple two-
sample t-tests would result in an increased chance of committing a statistical type 
I error, ANOVAs are useful in comparing (testing) three or more means (groups 
or variables) for statistical significance. ANOVA is a special case of regression, 
which was implemented using SPSS software (IBM SPSS statistics 19, USA).  
The mathematical model of ANOVA can be expressed as:  
Y = β0 + β1x1 + β2x2 … + β1…nx1…n + ϵ                (Equation 2-5) 
2.5.3 Artificial neural network (ANN) 
Artificial neural networks are computational models inspired by animals' central 
nervous systems (in particular the brain) that are capable of machine learning 
and pattern recognition (Gevrey et al., 2003). They are usually presented as 
systems of interconnected "neurons" that can compute values from inputs by 
feeding information through the network, as depicted in Fig. 2-9. ANN provides 
the most flexibility for situation, in which user may not have a clear understanding 
of the scope of information contained within data set, and therefore may not have 
specific hypotheses from which to begin an analysis.  
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Fig. 2-9. Structure of the neural network used in this study. F1, input layer of 
neurons comprising as many neurons as variables at the entry of the system; F2, 
hidden layer of neurons whose number is determined empirically; F3, output layer 
of neurons with a single neuron corresponding to the single dependent variable 
(Gevrey et al., 2003). 
Artificial neural networks are well established and many applications have been 
reported in pharmaceutical formulation and processing (Shao et al., 2006). The 
range of applications has been reviewed by Colbourn and Rowe (Colbourn and 
Rowe). Neural networks are useful in detecting complex non-linear relationships 
between a set of inputs and outputs and estimate magnitude of the relationships 
without requiring a mathematical description of how the output functionally 
depends on the input. The training process depends on the training vector and 
on the topology of the ANN. The ANN manages to converge if the training data 
are adequate to create the appropriate discriminations between the different 
output classes.  
In this study, there was shown to be some linkages between excipients and 
physical properties of particles. This section describes the modelling of 
experimental data able to provide some reliable indication of morphology and 
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performing outcomes of particles from knowledge of particles properties and their 
characteristics. In order to discover relations between the excipients and 
properties of formulation, pooled data from the experiment were analysed using 
commercially available ANN software (INForm v3.4, Intelligensys, UK). A 
description of this application and its utility for modelling pharmaceutical 
formulation and processing data has previously been given in (de Matas et al., 
2008). 
For neural network training purposes, processing parameters were treated as 
independent variables (inputs) and physical properties and morphology of 
particles as the response variable (output). In order to avoid overtraining of ANN, 
ANN model was established by leave-one-out cross validation technique. The 
database was divided into a training set (k-1 data records), a test set (1 data 
records) and a validation set (1 data records). Training and test data were used 
by the ANN to learn the cause effect relationships, inherent in the data set, whilst 
the validation data, which were excluded from training, were used to assess the 
predictability of generated models. 
2.5.4 Cross validation   
Due to small sample size, in order to avoid the over-fitting of ANN model, k-fold 
cross validation was chosen to validate the quality of models. Cross-validation is 
a model validation technique for assessing how the results of a statistical analysis 
will generalize to an independent data set. It is mainly used in settings where the 
goal is prediction, and one wants to estimate how accurate a predictive model will 
perform in practice (Mirzaie et al., 2014, Afshin Maleki et al., 2014). It is worth 
highlighting that in a prediction problem, a model is usually given a dataset of 
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known data on which training is run (training dataset), and a dataset of unknown 
data (or first seen data) against which the model is tested (testing dataset). The 
goal of cross validation is to define a dataset to "test" the model in the training 
phase (i.e., the validation dataset), in order to limit problems like overfitting and 
give an insight on how the model will generalize to an independent data set (i.e., 
an unknown dataset, for instance from a real problem). 
K-fold cross-validation is a model selection tool. The k-fold cross-validation splits 
the training-validation data set into k equally-sized blocks. At each stage, k-1 
blocks are used for estimating the model and the remaining block is used for 
computing its average prediction error (mean squared error, MSE). The blocks 
used for estimation are called the training data and the block used for prediction 
diagnostics is called the validation data. The process repeats itself until each 
single block is used as the validation data. The results from k different validation 
procedures are averaged to produce the overall cross-validation score. The 
cross-validation score is an estimate of the true prediction error on the training-
validation data set (stanfordphd).(stanfordphd)(stanfordphd)(stanfordphd)  
2.6 Conclusion  
The characterisation of the samples was studied using an array of analytical 
methods. Moreover, similarities and differences in the physical properties of such 
materials were also investigated. The supplied micronized drugs were similar to 
each other in terms of particle size and shape. The differences between materials 
characterised using DVS, DSC and XRPD were observed. Importantly, the 
physicochemical characterisation of the pharmaceutical materials shown in this 
chapter will be compared to those of processed particles in the following chapters. 
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Chapter 3 : Production of Inhalable Theophylline using Jet 
Milling, Wet Milling and Spray Drying  
3.1 Introduction  
The advantages of pulmonary delivery of drug have been reviewed and 
discussed in the previous chapter. From these findings, it can be estimated that 
inhalation of theophylline would be an ideal delivery methodology to avoid the 
side effects caused by high concentration of theophylline; and slower and 
uncontrollable metabolism yield by its oral administration, leading to better 
bioavailability and treatment performance (Cosio et al., 2004).  Manufacturing of 
inhalable theophylline requires powders with desirable characteristics. Among of 
micronizing techniques, jet milling and spray drying were widely used in industry 
product, while the wet milling can achieve nano-size particles (Peltonen and 
Hirvonen, 2010). 
In this study, jet milling, spray drying and wet milling were used to reduce the size 
distribution of theophylline. Jet milling reduces particle size via high velocity 
particle-particle collision. Spray drying is a one-step process that converts a liquid 
feed into a dried particle (Aulton, 2009), where feed solution is atomized from 
nozzle to form small droplets, and droplets contact with air and getting dry. The 
advantage of this technique is that it can be used for drying any type of fluid. In 
wet milling, micron size drug crystals are media milled in a water-based solution 
and reduced to nanometer-sized particles. This technique has been identified as 
a useful procedure to develop formulations of poorly-water-soluble compounds. 
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3.1.1 Aim and scope of the works 
The aim of this study is to produce micronized theophylline that has suitable 
morphology for aerosol dispersion, using jet milling, spray drying and wet milling. 
The high energy input of jet milling and spray dry can cause area of powder 
surface to become amorphous, which can lead to poor flowability and hinder the 
removal of the powder from an inhaler. The extraordinary reduction of particle 
size distribution in wet milling can cause a high level of agglomeration. Therefore, 
in order to develop inhalable theophylline, firstly it needs to investigate and 
compare the morphology changes caused by these processes. Additionally, 
aerodynamic behaviour of micronized particles has to be examined. In this study, 
Aeroliser® is used as a model device. The batch of sample that has the best 
aerodynamic property is selected for physical mixture.  Finally, the aerosolization 
performance of theophylline/budesonide physical mixture will be tested.  
3.2 Materials 
3.2.1 Active drugs 
The active drugs used in this experiments can be found in Chapter 2.2.1.  
3.2.2 Chemicals for IGC 
All chemicals used for IGC have been indicated in Chapter 2.2.3. 
3.3 Methodologies   
3.3.1 Micronization of theophylline 
3.3.1.1 Jet milling 
The processing of jet milling has been illustrated in Chapter 2.3.1.  
3.3.1.2 Spray drying  
The processing of spray drying has been explained in Chapter 2.3.2.  
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This solution was prepared by ultrasonication at room temperature (20 ◦C). The 
solvent contains 80% (v/v) ethanol and 20% (v/v) deionised water, where the 
concentration is about 2.9%W/V.  
3.3.1.3 Wet milling 
The procedure of wet milling has been demonstrated in Chapter 2.3.3.   
3.3.2 Thermal analysis 
The procedure of thermal analysis (TGA and DSC) have been described in 
Chapter 2.4.3.  
3.3.3 X-ray diffraction (XRD) analysis 
The processing of XRD has been mentioned in Chapter 2.4.2.  
3.3.4 Visualisation of particles 
The SEM analysis has been described in Chapter 2.4.4.    
3.3.5 Particle sizing 
The Measurements of particle size distributions of particle have been mentioned 
in Chapter 2.4.4.  
3.3.6 Aerodynamic assessments 
The aerodynamic assessments were analysed by next generation impactor (NGI). 
The descriptions have been elucidated by Chapter 2.4.7.2.  
3.3.7 Drug quantification 
This analysis has operated by high performance liquid chromatography (HPLC). 
The processing has been demonstrated in Chapter 2.4.6. 
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3.4 Results and discussion  
3.4.1 Reduction of particle size 
Laser diffraction was used to analyse the size distribution of micronized 
theophylline. Following jet milling, theophylline caused the powder to change 
colour from transparent to white. It was observed that the size of powder was 
reduced dramatically to less than 5µm, which has been indicated in Table 3-1. 
Table 3-1 displays the particle size distributions of raw material and processed 
samples. It can be observed that the geometric particle size distribution of raw 
theophylline (TH00) is out of measurement range (between 0.2 and 87.5µm). The 
batch TH01 has a size distribution of D50=1.20µm±0.13, VMD=1.23µm±0.12, 
respectively. The wet milling sample has a particle size of approximately 400nm 
at 45 mins in suspension, but after air drying the final sample (TH03), the size 
distribution increases dramatically. Table 3-1 also indicates that the spray drying 
sample (TH02) contains big particle, which is 74.78±0.76µm of D90.   
Table 3-1 Particle size distribution of TH00, TH01, TH02 and TH03 (raw 
theophylline: Th00; jet milling: TH01; spray drying: TH02; wet milling: TH03) 
Samples Particle Size Distribution  
D10 (µm) D50 (µm) D90 (µm) (±SD) 
TH00 11.18±0.2 27.74±2.4 87.5 (Maximum) 
TH01 0.74±0.053 1.20±0.13 1.76±0.23 
TH02 0.74±0.03 4.21±0.18 74.78±0.76 
TH03 0.885±0.21 2.91±0.21 54.815±0.28 
According to the size distributions of each batches, all the batches meet the 
requirement for the inhalable range (1-5µm) (de Boer et al., 2002). Particularly, 
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jet milling could produce a micro-particle with narrower size distribution, rather 
than wet milling and spray dry.  
3.4.2 Thermal analysis (differential scanning calorimetry (DSC) and 
thermogravimetric analysis (TGA)) 
Fig. 3-1 is the DSC profile of raw theophylline and micronized samples. The 
micronized samples, TH01, TH02 and TH03, showed no evidence of conversion 
to amorphous form as observation for raw theophylline (TH00) can be seen in the 
DSC profile of Fig. 3-1.  
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(b). Melting point of samples 
Fig. 3-1. DCS plots for raw theophylline (TH00) and its samples milled using jet 
mill (TH01), spray drying (TH02) and wet mill (TH03). (a) is endotherm that is 
below 100◦C, and (b) indicate the heat change over 240◦C.  
However, as can be found in Fig. 3-1-b, DSC data of TH03 reveals that an 
endotherm was observed below 100 ◦C. This finding is in good agreement with 
the figure published in the literature (Suihko et al., 1997). This endotherm is 
related to theophylline monohydrate, which concurs with the findings of TGA in 
Fig. 3-2. As can be seen in Fig. 3-2, TH03 loss approximately 9% of mass at 
temperature of 80 ◦C. This weight lost is to be the dehydration of TH03, which 
suggests that anhydrous theophylline is converted to monohydrate theophylline 
(TH03) during wet milling.  
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Fig. 3-2. TGA profiles of the Theophylline before and after milling using jet mill 
and wet mill, 8.719% of weight loss was found at temperature of 79 ◦C 
3.4.3 Characterization of particles  
3.4.3.1 PXRD analysis 
Fig. 3-3 is the patterns of PXRD. The powder diffraction patterns obtained from 
the micronized theophylline (TH01, TH02, and TH03) are compared with the 
powder patterns of pre-milled sample (TH00). According to Fig. 3-3, no notable 
evidence of amorphous theophylline are observed. 
As can be discovered in patterns of DSC as shown in Fig. 3-2, the peaks of 
micronized samples are low intensity, slightly broader and less well defined. In 
XRD figure, new peaks are observed at 32o and 42o, whilst all peaks accordant 
with the recommended sample TH00 as described in Fig.3-3. These changes are 
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caused by size reduction. Owing to size reduction, the fresh surfaces has been 
exposed.  
Moreover, in pattern of TH03, there are several new peaks on 9o, 12o and 14o, as 
described in (Suihko et al., 1997, Otsuka and Kinoshita, 2010), these peaks 
correspond to those known for theophylline monohydrate.  
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Fig. 3-3. XRPD patterns produced by Theophylline before and after micronizing 
using jet mill, spray drying and wet mill. 1: raw theophylline (TH00); 2: jet milling 
sample (TH01); 3: wet milling sample (TH03), new peaks on 9o, 12o and 14o were 
indicated by arrow; 4: spray dried sample (TH02)  
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3.4.3.2 Inverse gas chromatography (IGC) 
In order to detect the surface energy change after processing, IGC analysis has 
been carried out on raw material and micronized samples. These are the raw 
material TH00, spray drying TH02; and the TH01 and TH03 forms after jet and 
wet milling. The obtained data shows that dispersive energies are greater for the 
processed samples compared with their pre-micronized counterparts (45.8±1.9 
mJ/m2). The spray drying TH01 has value of 63.83±0.52 mJ/m2. The milled forms 
have values of 63.00±0.45 mJ/m2 and 66.40±0.67 mJ/m2 for TH01 and TH03 
respectively. According to specific energies analysis of Fig. 3-4, THF and ethyl 
acetate probes have a greater affinity for the TH01 and TH02, indicating the 
exposure of acidic groups. There a large STDEV error in TH03 was detected. 
This result suggests that TH03 exposed acidic groups after wet milling, however 
some acidic groups was hydration reaction, which respond what have been 
discovered in previous DSC, TGA, and PXRD studies. The chloroform probe has 
a less affinity for the samples, again demonstrating the exposure of acidic groups 
on surface.  
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Fig. 3-4. Specific energies obtained for the TH00, TH01, TH02 and TH03. Energy 
values are in mJ/m2.  The numbers resented in graph are the average results for 
specific energies. 
3.4.3.3 Scanning electron microscopy (SEM) 
All materials were analysed by SEM under a range of magnifications. The 
obtained results are illustrated in Fig. 3-5. It can be seen that the size of particle 
(Fig. 3-5-B, C, D) is reduced dramatically compared with the raw materials (Fig. 
3-5-A). The shape of particles is irregular; and the small particles aggregate 
together.  
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D 
Fig. 3-5. SEM of all materials. A=raw theophylline x100, B=TH01 x5000, C=TH02 
x3000, D=TH03 x5000 
The laser diffraction data is described in Table 3-1, which demonstrates that the 
micronized batch TH01 has a narrower particle size distribution than the TH02 
and TH03. SEM data confirms this result, which shows that smaller particles 
existed with a higher level of particle agglomerations for TH02 (Fig. 3-5-C), but 
SEM found the TH02 particles form a pollen-like particles. Fig. 3-5-D is the SEM 
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result of wet milling batch TH03. It can be observed that TH03 is smaller than 
TH02 and TH00, however the fine particles of TH03 are tight together and 
become larger, which confirms the observation of laser diffraction for TH03.  
3.4.3.4 Aerodynamic behaviour 
The assessment of the aerodynamic behaviour was test using the NGI. According 
to the morphology and thermal analysis, TH03 has been proved that it is the 
monohydrate theophylline. Thereby, TH01 and TH02 were used to characterize 
the aerodynamic properties. In the aerodynamics analysis, TH01 and TH02 were 
delivered by mixed/absented with lactose. The assessment results and sample 
batches, i.e. TH01, TH02, blend I, blend II, blend III, and blend IV, are presented 
in Table 3-2. All the results are the average of each analysis that was repeated 
three times.  
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Table 3-2 The aerodynamic properties of different preparations of resultant samples and lactose using Aeroliser® at 60 L/min; TH01: 
jet milling sample, delivery drug only; TH02: spray drying sample, delivery drug only; Blend I: physical mixture of TH01 and lactose 
ML001; Blend II: physical mixture of TH02 and ML001; Blend III: physical mixture of TH01, micronized budesonide(BU) and lacto 
ML001; Blend IV: physical mixture of TH02, BU and ML001  FPF: fine particle fraction; MMDA: mass median aerodynamic diameter 
Dispersed samples FPFloaded (%) FPFemitted (%) Impaction recovery (%) MMDA 
   Theophylline  Budesonide 
TH01 9.6±5.3 22.4±3.0 33.3±8.9 - 4.5±0.8 
TH02 11.9±2.7 21.0±2.9 33.0±8.9 - 5.1±0.02 
Blend I (ML001+TH01) 19.7±1.1 20.9±1.1 9.1±2.6 - 3.6±0.1 
Blend II (ML001+TH02) 16.4±1.0 17.5±1.0 15.1±3.6 - 3.6±0.1 
Blend III (ML001+BU+TH01) 26.8±23.1 34.9±9.3 11.7±0.08 2.5±0.01 6.4±0.9 
Blend IV (ML001+BU+TH02) 25.3±3.4 27.7±1.6 17.9±0.39 2.2±0.01 7.1±0.2 
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As shown as in Table 3-2, TH01 performances better aerodynamic behaviour, 
resulting in higher FPFemitted of 22.4%, rather than the spray dried sample with 
approximate 21% of FPFemitted. Moreover, difference powder shapes and sizes 
would impact on airway deposition(Pilcer and Amighi, 2010). According to the 
above discussion and the SEM pictures (Fig. 3-5), TH01 and TH02 show different 
particle sizes and different shape. TH01 has a narrower size distribution of 0.74-
1.76µm, compared to TH02 that is from 0.74 to 74.78µm. Both of them are 
crystalline form, however, spray dried made TH02 forms spherical shape of 
particle, which is easier to aggregation, rather than the irregular shape of TH01 
(Fig 3-5), as irregular surface has lower cohesiveness. Furthermore, the MMDA 
of TH01 is less than 5µm (4.5µm), while TH02 is 5.1µm, but TH02 still is a 
potential formulation for inhalation, because it is spherical particle formed by 
needlike crystal, which contributes to a smaller aerodynamic diameter and 
enhances the flowability and the aerosol performance of powders emitted from 
the capsule (Chew et al., 2005). Thereby, according to the Fig. 3-6, the amount 
of API in throat is higher that the milled batches, however the deposition of the 
particles is significantly higher in the deeper stages such as stage 6. 
Additionally, it has been found absence of lactose result in a relatively lower 
FPFload and FPFemitted as expected due to the poor flowability of powder. There 
were more APIs retained in capsule in TH01 and TH02. This phenomenon has 
been reported in some articles (Yeh et al., 1976, Pilcer and Amighi, 2010, 
Dickhoff et al., 2003), which describe the importance of lactose being carrier. 
Lactose helps particles to deposit in deeper stages (Fig. 3-6), and reduces the 
interparticle forces which make the powder cohesive.  
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A. Overall Stages 
 
B. Magnified Stage 5, 6, 7 and MOC 
Fig. 3-6. Deposition of TH01, TH02, Blend I, and Blend II on the NGI stages. 
As expected, analysis of the simultaneous deposition of theophylline and 
budesonide from the physical mixture formulation should indicate a consistent 
ratio. Table 3-3 is the NGI analysis to verify the simultaneous deposition of 
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physical mixtures. In the mixture, theophylline is 20 (±2%) times more than 
budesonide. According to Table 3-3, there is no significant difference between 
these two blends (P>1).  This stage by stage analysis find inconsistent ratio of 
theophylline to budesonide, indicating severe particles segregation occurred 
during dispersion. The adhesion of APIs is broken by shear force from the air 
and/or collision between the particles or between the particles and the inhaler 
device during dispersion. Moreover, it can be found more theophylline landed in 
upper stage (Throat to stage 2) than that of budesonide (Table 3-3). This is the 
evidence that there is high level of agglomeration in micronized theophylline. 
Nevertheless, theophylline has better aerosolization performance in Blend IV, as 
sphere shape of TH02 which spherical nature resulting in less contact with 
budesonide surface and better de-agglomeration (Chew et al., 2005, Muhammad 
et al., 2013). This also enhance more budesonide depositing in lower stages 
(stage 5 to MOC). Due to the high dose of theophylline, the large size theophylline 
become to aerosol carrier. Compare to milled theophylline, the spray drying 
sample (TH02) has a wider size distribution and a lower interparticle force, which 
help balance of cohesive and adhesive force and reduce the agglomeration of 
micro-budesonide, leading to a lower deposition of budesonide.  
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Table 3-3 The ratio of theophylline:budesonide in each stage of NGI  
 Ratio of  theophylline/budeosnide in each stage of NGI   
 Blend III Blend IV 
Throat 644.7±874.3 150.6±19.9 
Pressep 198.2±258.9 51.8±17.8 
Stage 1 81.7±22.5 87.2±9.6 
Stage 2 70.3±11.4 63.9±5.1 
Stage 3 36.6±7.1 32.8±5.1 
Stage 4 17.9±4.7 15.6±0.6 
Stage 5 8.0±2.1 7.9±0.8 
Stage 6 5.7±1.9 8.0±2.0 
Stage 7 3.0±0.8 9.5±3.1 
MOC 20.3±9.6 204.2±149.1 
 
3.5 Conclusion 
In conclusion, the milling process and spray drying technique have been 
successfully employed in engineering micro particles of theophylline. These 
processes produce theophylline particles, are crystalline and these particles 
exhibit no polymorphic variations upon processing, although wet milling generate 
theophylline monohydrate. The micronized theophylline particles possess 
desired physical properties with appropriate particle size for lung delivery. 
Moreover, in vitro performance analysis, the finding suggests that the better 
morphological characteristics of TH01, has a greater delivery than the TH02. 
Although the particle size of the TH02 was not optimal for delivery to the lungs, 
particles are unique as the urchin-like particle resulted in a smaller aerodynamic 
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diameter. Compared with raw theophylline, the result shows that the micronized 
theophylline exposes more acidic groups and has higher surface energy and 
hygroscopicity than raw materials. These effects can potentially lead to relate 
changes in solid-state properties and interfacial properties of particles, which will 
impact aerosol and lung particle deposition.  
These results show that the theophylline can be processed with the desired 
property function and produced for inhaled dosage forms via milling and spray 
drying. 
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Chapter 4 : Combination Particles Containing Theophylline 
and Budesonide: Formulation and Aerodynamic Assessment.  
4.1 Introduction 
In this chapter, a formulation was processed using a spray dry production of dual 
particles containing theophylline and budesonide for pulmonary delivery of drug. 
In contrast to the commercial physical mixture DPI products on the market, all 
APIs were processed simultaneously to obtain particles which contain both APIs. 
The objective of this study is to characterise the physicochemical properties of 
the combination particles. Also, the potential suitability of the spray dried powders 
for use in DPIs is of interest. For the used mixtures, the weight ratio of 100:5 
(theophylline to budesonide, TH:BU) is chosen based on the therapeutic range 
of the clinical dosage of inhaled budesonide  (Lim et al., 2000), and published 
dosage of inhaled theophylline (Barnes et al., 2010). To satisfy this required ratio, 
6mg of theophylline and 0.3mg of budesonide are in a capsule to be used in this 
experiment. 
4.2 Materials and Methodologies 
4.2.1 Materials 
The materials used in this study have been mentioned in Chapter 2.2. 
4.2.2 Preparation of the systems 
The spray drying process is same to what has been used in Chapter 2.3.2. For 
all experiments, both drugs were dissolved in the solvent under ultrasonication. 
The drugs were used in a weight ratio of 100:5 between theophylline and 
budesonide dissolving in solution of 80% (v/v) methanol and 20% (v/v) deionised 
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water. Different ratios of excipients were tested for their effects on properties of 
combination particles. Those were Polyvinylpyrrolidone PVP (Kollidon 25, BASF, 
Ludwigshafen, Germany) and hydroxypropylmethyl cellulose (HPMC, Metolose 
60 SH 50, Shin-EtsuChemical,Tokyo, Japan). They were used in a range from 
0.05% to 0.5%. Table 4-1 describes the experimental design for this study.  
Table 4-1 Experiment was a full factorial design (HPMC: -1=0% w/v, 0=0.25% 
w/v, 1=0.5% w/v; PVP: -1=0%w/v, 0=0.05% w/v, 1=0.1% w/v)  
 HPMC %w/v PVP %w/v 
TB-1 -1 -1 
TB-2 -1  0 
TB-3 -1  1 
TB-4  0 -1 
TB-5  0  0 
TB-6  0  1 
TB-7  1 -1 
TB-8  1  0 
TB-9  1 -1 
 
 
4.2.3 Particle characterisation methods 
The particle characterisation methods have been fully explained in Chapter 2.4. 
These methods are thermal analysis, XRD, SEM, particle sizing and aerodynamic 
analysis and they can be found in Chapter 2.4.3, Chapter 2.4.2, Chapter 2.4.4, 
Chapter 2.4.1 and Chapter 2.4.7 respectively. 
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4.2.4 Assessment of theophylline solubility 
For solubility studies, the theophylline was dissolved with the respective 
excipients mixture, and an excess of drug remains at the bottom of the glass vial. 
The vials were closed tightly and shaken for 48 h at room temperature (20 ◦C). 
During shaking process, it was controlled and checked regularly to see whether 
a residuum remains present in each vial. If not, further drug was added to the vial. 
After 48 hrs, the supernatant was filtrated and drug quantification was performed 
as described below. 
4.2.5 Drug quantification 
This assessment has been illustrated in Chapter 2.4.6.  
4.2.6 Statistical analysis  
Fig. 4-1 shows the detailed process of the statistical analysis used in the 
presented work. 
 
Fig. 4-1. Flowchart of statistical analysis  
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4.2.6.1 Regression analysis and ANOVA analysis 
As can be found in Fig. 4-1, regression and ANOVA analysis are used to 
determine the important independent factors at the initial stage of the statistical 
analysis. Regression and ANOVA analysis and model generation which have 
been described in the Chapter 2.5.2 will be implemented in this section.  
In this study, firstly it is to optimise the processing parameters of spray drying. 
The regression model of response variables were observed values of the 
solubility, the ratio between budesonides and theophylline of combination 
particles; and the D50 particle size, and explanatory variables, i.e. HPMC, PVP, 
inlet temperature, atomization, air flow rate, and feed rate. And then, the ANOVA 
analysis was applied for further studies. The primary purpose of ANOVA is to 
understand if there is any interaction between the independent variables on the 
dependent variable and detect the important factors. In this study, ANOVA 
methodology was to select the important factors which cause significant 
influences on particle size and particle composition. The significance of variables 
were judged by p-value. A low p-value (< 0.05) indicates that predictor is likely to 
be a meaningful addition to model because changes in the predictor's value are 
related to changes in the response variable. The predictors that have a low p-
value were selected to establish regression model. The fit of a regression model 
can be judged with calculation of the correlation coefficient, R2, defined as the 
correlation between the observed values of the response variable and the values 
predicted by the model (Paul R. Kinnear and Gray., 2008). This model was 
generated using SPSS software (IBM SPdSS statistics 19, USA).  
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4.2.6.2 ANN modelling 
The regression model had a small R2, which has been found in the above 
regression analysis. This result suggested the regression model is not suitable 
for this study. Therefore, as illustrated in Fig. 4-1, the ANN analysis was 
employed to discover the linkages between the excipients and physical properties 
of particles. In this analysis, pooled data from the experiment were analysed 
using commercially available ANN software (INForm v3.4, Intelligensys, UK). A 
description of this software and its utility for modelling pharmaceutical formulation 
and processing data has previously been given in (de Matas et al., 2008). 
In neural network training process, HPMC and PVP were treated as independent 
variables (inputs), where the solubility, the ratio between budesonides and 
theophylline of combination particles (TH:BU), and the D50 particle size as the 
response variable (output). Due to the available amount of data set, the ANN 
model was established by leave-one-out methodology. The database is divided 
into a training set which has 7 data records, a test set with 1 data records and a 
validation set with 1 data records. Training and test data sets are used by the 
ANN to learn the cause effect relationships and inherent characteristics in the 
data set, while the validation data sets which are excluded from training, are used 
to assess the predictability of generated models. 
4.3 Results and discussion 
4.3.1 Optimization of spray drying process  
The particles used for pulmonary drug delivery have the ability to manipulate and 
control a variety of parameters of spray drying such as solvent composition, 
solute concentration, solution and gas feed rate, temperature and relative 
humidity, droplet size, etc (Pilcer and Amighi, 2010). In this study, the spraying 
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nozzle and solution composition were fixed. The two levels of spray drying 
processes parameters were applied to investigate influences on particle size and 
composition. The data was analysed by ANOVA to select the significant factors 
that cause important effects on particles. The independent variables were 
excipients, i.e. HPMC and PVP, and spray drying parameters, i.e. inlet 
temperature, atomization, air flow rate, and feed rate. Table A1 in Appendix 
presents the observed results. This result was analysed by factorial ANOVA and 
regression to see the important factors and detect the reactions between the 
variables.  
According to the ANOVA and regression results which were shown in Appendix’s 
Table A2 to A5, it suggests that HPMC and PVP are significant factors which 
influence ratio of theophylline and budesonide in particle with p-value<0.000. It is 
also found that the particle size is associated with concentration of HPMC. In 
contrast to HPMC, particle size of PVP does not have effects. Interestingly, it is 
noticeable that the spray drying process parameters do not have significant 
influences in this study. Due to these findings, excipients were used to develop 
models to predict and control the particle size and composition. 
4.3.2 Generation of models: solubility of theophylline, and particle size and 
composition 
As found in previous section 4.3.1, the fixed process parameters were 
manipulated in this experiment. The expansion of level of excipients was selected. 
In this study, the 3 level of concentrations of excipients were operated to obtain 
quality models which can be used to explain the association between excipients 
and particles. Table 4-2 is the observed results of this study, which is used to be 
analysed by regression and ANN.    
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Table 4-2 Summary of result, where TH is theophylline; BU is the budesonide; 
TH:BU is the ratio between theophylline and budesonide.   
  HPMC PVP TH:BU Solubility 
(mg/ml) 
Size (VMD) (µm) 
TB-1 -1 -1 14.90±3.33 0.281±0.034 8.19±2.80 
TB-2 -1  0 16.79±2.21 0.306±0.012 35.68±10.85 
TB-3 -1  1 16.94±2.32 0.310±0.003 15.62±2.36 
TB-4  0 -1 19.66±1.87 0.323±0.021 13.72±2.40 
TB-5  0  0 20.03±2.13 0.330±0.001 9.16±1.23 
TB-6  0  1 20.62±0.43 0.326±0.002 7.66±1.02 
TB-7  1 -1 19.4±1.61 0.336±0.020 8.99±0.33 
TB-8  1  0 17.96±3.13 0.335±0.006 8.81±0.6 
TB-9  1  1 20.10±2.16 0.340±0.003 5.76±0.63 
 
 
4.3.2.1 Regression model generation  
The regression model was established by implementing SPSS software. The 
result is displayed in Table 4-3 and 4-4.  According to Table 4-3 and 4-4, HPMC 
and PVP do not cause any effects on the ratio between theophylline and 
budesonide (TH:BU), due to the p-value of them are greater than 0.05.  
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Table 4-3 Regression model of TH:BU 
Regression Statistics 
Multiple R 0.71164892 
R Square 0.506444185 
Adjusted R Square 0.34192558 
Standard Error 1.574181774 
Observations 9 
 
  Coefficients Standard Error p-value 
Intercept 18.48941938 0.524727 3.48E-08 
HPMC 1.470870924 0.642657 0.062052 
PVP 0.615870924 0.642657 0.374908 
 
 
Table 4-4 Summary of ANOVA data: regression model of TH:BU  
ANOVA      
  df SS MS F Significance F 
Regression 2 15.25655 7.628275 3.07834 0.120229 
Residual 6 14.86829 2.478048   
Total 8 30.12484       
 
To further verify the finding, the factorial ANOVA model was applied to optimize 
regression models, where TH:BU was dependent variables; and excipients were 
set as independent variables. The summary of ANOVA model is shown in Table 
4-5 and the mathematical model can be expression as below: 
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Y = β0 + β1x1 + β2x2 + β11x11 + β22x22 + β12x12 + β112x112 + β122x122 +
β1122x1122 + ϵ                                  (Equation 4-1) 
Where the indicator variable, x1=HPMC, x2=PVP; the β is the effects coefficient 
for the main effects of factors (HPMC, PVP), β12 , β13  … β1234 are the effect 
coefficients for the interactions of variables. 
As can be observed in Table 4-5, it suggests that the change of TH:BU is related 
to HPMC concentration with a p-value of 0.006. However, its regression model 
which is shown in Table 4-6 has lower R2 of 0.43, therefore, this result indicates 
that regression analysis is not suitable in this study. 
Table 4-5 ANOVA model of the ratio between theophylline and budesonide 
(TH:BU)  
Tests of Between-Subjects Effects 
Dependent Variable: TH:BU 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
HPMC 5.384 2 2.692 13.666 .006 
PVP .469 2 1.256 .273 .770 
HPMC * PVP 3.518 2 1.759 .397 .689 
HPMC2*PVP 4.943 2 2.471 .589 .584 
PVP2 * HPMC 17.723 2 8.861 4.287 .070 
HPMC2 11.721 1 11.721 4.458 .073 
PVP2 .237 1 .237 .055 .821 
HPMC2 * PVP2 3.072 1 3.072 .795 .402 
Error .000 0 .   
Total 3106.853 9    
a. R Squared = 1.000 (Adjusted R Squared = .) 
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Table 4-6 Summary of regression model of TH:BU, which was generated using 
HPMC  
Regression Statistics 
Multiple R 0.656429 
R Square 0.430899 
Adjusted R 
Square 0.349599 
Standard Error 1.564977 
Observations 9 
 
  Coefficients Standard Error p-value 
Intercept 18.48942 0.521659 3.69412E-09 
HPMC 1.470871 0.638899 0.054813468 
Moreover, the results for the regression analysis of particle sizes are shown in 
Table 4-7 and 4-8 and its corresponding ANOVA study is given in Table 4-9. 
These results have confirmed that excipients did not influence on the particle size, 
because that the p-value of all independent variables are greater than 0.05. 
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Table 4-7 Regression model of particle size  
Regression Statistics 
Multiple R 0.681661 
R Square 0.464661 
Adjusted R Square 0.286215 
Standard Error 2.531861 
Observations 9 
 
  Coefficients Standard Error p-value 
Intercept 8.652222 0.843954 5.0248E-05 
HPMC -2.28167 1.033628 0.06938794 
PVP -0.59833 1.033628 0.58373982 
Table 4-8 Summary of ANOVA data: regression model of particle size 
ANOVA      
  df SS MS F Significance F 
Regression 2 33.3840 16.6920 2.6039286 0.153421 
Residual 6 38.4619 6.41032   
Total 8 71.84596       
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Table 4-9 ANOVA model of particle size of dry powder  
Tests of Between-Subjects Effects 
Dependent Variable: Particle size 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
HPMC 33.307 2 16.106 2.438 .168 
PVP 19.471 2 1.811 .159 .856 
HPMC * PVP 14.408 2 7.204 .753 .511 
HPMC2 * PVP .380 2 .190 .016 .984 
PVP2 * HPMC 10.606 2 5.303 .520 .619 
HPMC2 .975 1 .975 .096 .765 
PVP2 1.473 1 1.473 .147 .713 
HPMC2 * PVP2 .044 1 .044 .004 .950 
Error .000 0 .   
Total 745.595 9    
a. R Squared = 1.000 (Adjusted R Squared = .) 
Furthermore, the relationship between solubility and excipients is discovered. 
According to the regression analysis of Table 4-10, the model has small value of 
p (p˂0.05). This gives a good indication of HPMC has significant effects on 
solubility of theophylline (ST) at room temperature. Meanwhile, it is also noticed 
in Table 4-11, the model of ST has higher R2 of 0.84 as well as its Significance 
F˂ F in its ANOVA data. This demonstrates that the model is reliable for predicting 
ST. To further optimize the result of regression analysis, a factorial ANOVA 
method is carried out in the following study. 
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Table 4-10 Regression model of solubility of theophylline 
Regression Statistics 
Multiple R 0.917792 
R Square 0.842342 
Adjusted R Square 0.789789 
Standard Error 0.008672 
Observations 9 
 
  Coefficients Standard Error P-value 
Intercept 0.320752 0.002891 3.6114E-11 
HPMC 0.019093 0.00354 0.00167456 
PVP 0.006101 0.00354 0.13559148 
 
 
Table 4-11 Summary of ANOVA data: regression model of solubility of 
theophylline 
ANOVA      
  df SS MS F Significance F 
Regression 2 0.00241 0.00120 16.028486 0.003919 
Residual 6 0.00045 7.52E-05   
Total 8 0.00286       
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Table 4-12 summarises output of ANOVA study. According to this table, HPMC, 
PVP, and PVP2 * HPMC are important variables to theophylline solubility. These 
factors are used to generate the regression model, which has been shown in 
Table 4-13. Compared Table 4-10 with Table 4-13, it was found that R2 of the 
model was improved from 0.84 to 0.86; and also in Table 4-14, F > F-sig. 
demonstrates that this model is reliable for predicting ST. Therefore, according 
to the pervious finding, regression model can be performed by adopting the 
following equation. Mathematical model of theophylline solubility can be 
described as: 
Y = β0 + β1x1 + β2x2 + β122x122 + ϵ                        (Equation 4-2) 
Y = 0.321 + 0.015x1 + 0.006x2 + 0.007x122 + ϵ 
R2=0.86 
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Table 4-12 ANOVA model of the solubility of theophylline that were used for spray 
drying 
Tests of Between-Subjects Effects 
Dependent Variable: Solubility 
Source 
Type III Sum 
of Squares df 
Mean 
Square F Sig. 
HPMC .000 2 .001 12.826 .007 
PVP .000 2 .000 .306 .047 
HPMC * PVP .000 2 .000 .315 .741 
HPMC2*PVP .000 2 .000 .480 .640 
PVP2 * HPMC .002 2 .001 6.229 .034 
HPMC2 .000 1 .000 .339 .579 
PVP2 .000 1 .000 .103 .758 
HPMC2 * PVP2 .000 1 .000 .295 .604 
Error .000 0 .   
Total .929 9    
a. R Squared = 1.000 (Adjusted R Squared = .) 
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Table 4-13 Summary output of regression model, which was built between 
(HPMC, PVP, and PVP2 * HPMC) and theophylline solubility that was at room 
temperature  
Regression Statistics 
Multiple R 0.92891178 
R Square 0.862877095 
Adjusted R Square 0.780603353 
Standard Error 0.008859284 
Observations 9 
 
  Coefficients Standard Error P-value 
Intercept 0.32075156 0.002953 1.25E-09 
HPMC 0.01466739 0.006264 0.066268 
PVP 0.00610119 0.003617 0.152428 
HPMC*PVP2 0.006639135 0.007672 0.426418 
Table 4-14 Summary of ANOVA data: regression model of solubility of 
theophylline (independent variables are HPMC, PVP, and PVP2 * HPMC)  
ANOVA      
  df SS MS F Significance F 
Regression 3 0.002469 0.000823 10.48788 0.01347 
Residual 5 0.000392 7.85E-05   
Total 8 0.002862       
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4.3.2.2 Generation of ANN model  
As discussed in section 4.3.2.1, regression technique has limited capabilities to 
excavate the potential connections between excipients and particles. In order to 
establish a more reliable and accurate mathematical model that defines the 
relationship between excipients and physical properties of particles, the more 
sophisticated statistical learning model – ANN was applied in this study. This ANN 
models were programmed and setup using INForm v3.4. The training time is 
different slightly for networks with different numbers of hidden layers, nodes and 
transfer function. For this type of model, it was established by one hidden layer 
and two nodes to prevent over-fitting. 
The R2 of regression model and ANN model on each output are indicated in Table 
4-15. As shown in Table 4-15, it is clear that regression analysis only capable to 
conduct precise predictions of theophylline solubility with R2 value of 0.86, 
whereas neural network analysis could be used for generation of models of both 
theophylline solubility and TH:BU with R2 value of 0.90 and 0.78 respectively. 
Table 4-15 Correlation coefficient R2 of regression model and ANN model on 
solubility of theophylline in solutions, TH:BU, D50 particles size. [Solution: 
saturated solution (about 3%, w/v); solvent: 80% Methanol+20% Deionised 
Water]. 
 R2 of observed versus predicted value  
 Regression  ANN 
Solubility of theophylline  0.86 0.90 
TH:BU 0.51 0.78 
D50 particle size  0.46 0.24 
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The ANN model of theophylline solubility is formed by using transfer function of 
Symmetric Sigmoid and output transfer function of Asymmetric Sigmoid. 
Compared with regression model in Fig. 4-2, both of the models have same 
tendency, where ANN and regression models have high R2 of 0.9 and 0.84, 
respectively. This leads to evident that existence of a strong connection between 
the excipients and solubility of theophylline.  
 
Fig. 4-2. Solubility of theophylline observation data and its regression and ANN 
model.  
Moreover, Fig. 4-2 shows the predictions are closed to the observation data 
where the mean squared error (MSE) of ANN model is 3.43 x 10-5 and regression 
model is 5.01 x 10-5. Owing to availability of small data set, the ANN model was 
further validated using cross validation method. This has resulted in a low cross 
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validation error of 1.40 x 10-5. This result proves that the ANN model of 
theophylline solubility is not overfitting or underfitting and leads to further confirm 
that ANN model is reliable and accurate enough for prediction and estimation of 
ST.  
On the other hand, the ANN model of TH:BU was generated from Asymmetric 
Sigmoid of transfer function and Tanh of output transfer function. From the 
presented results from Table 4-15, it is clear seen that ANN model leads to better 
R2 of 0.7776, compared to R2 of 0.506 of regression model. This result reveals 
that ANN model could be able to predict a better value for TH:BU ratio. To check 
whether occurrence of overfitting in the predicted ANN model, it is to compare the 
regression model and ANN model to investigate whether they have similar 
tendency, and again cross validation method is applied in ANN model. As can be 
observed in Fig.4-3, ANN model has similar tendency to regression model, but 
the there is a big difference between ANN result and regression result at sample 
of TB-1 to TB-3, in contrast ANN model has a small cross validation error of 1.15, 
so that this model does not be over trained. Therefore, TH:BU model can be 
produced by ANN.  
According to the above discussion, it leads to conclusion that ANN is better than 
regression analysis in term of producing better models for theophylline solubility 
and TH:BU ratio.  
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Fig. 4-3. The predicated and observed result for the ratio between theophylline 
and budesonide in combination particles (TH:BU), including regression model 
and ANN model.  
4.3.3 Influence of excipient  
It has been well known that surface active substances can affect particle size by 
rapidly covering new surfaces, which could inhibit  crystal growth (Westmeier and 
Steckel, 2008). It also has been proved that a hydrophilic agent with surface 
activity help the powder absorbs the water and thus increases the dissolution in 
the lung fluid (Raghavan et al., 2001).Therefore, different ratios of excipients were 
tested for their influence on solubility of theophylline, particle size and 
aerodynamic behaviour of the combined particles. The experiment group was 
designed as shown in Table 4-1.  
In this study, it can be found that solubility of theophylline is related to 
concentration of excipients. As can be seen in Fig.4-4, excipients enhance its 
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solubility. By further examining Fig. 4-4, it was also found that there is a slightly 
raise in average solubility by increasingly concentration of PVP from 0.0% to 0.05% 
or 0.1%, and small changes when introducing solubility of high concentration of 
HPMC. 
 
Fig. 4-4. Excipients effect on solubility of theophylline (solvent: 80% Methanol+20% 
Deionised Water) 
As discussed in chapter 4.3.2, those data was used to establish a neural network 
model via ANN software, where the R2 =0.901 of model demonstrates a good 
quality prediction. This model is performed by Matlab surface fitting tool and it is 
plotted in Fig. 4-5. 
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Fig. 4-5. Response surface model of Matlab in accordance with the neural network model: predicted solubility at the different 
concentrations of excipients, where R2 is 0.9.
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As illustrated in Fig. 4-5, individual excipient can be able to cause increase in 
solubility of theophylline, but the solubility become steady when HPMC and PVP 
use together, however, the model reveals that HPMC causes significant effects 
in accordance with Fig. 4-5. The solubility rises up remarkably by increasing 
concentration of HPMC. Additionally, the ratio of theophylline to budesonide in 
combination particles also has been modelled by ANN. The R2 of the model is 
0.75, which is described as Fig. 4-6. As can be seen in Fig. 4-6, theophylline is 
about 20 (±3) times more than budesonide in the combination particles. It 
indicates that neither HPMC nor PVP produce any remarkable impacts on the 
ratio of theophylline:budesonide, nevertheless, higher concentration of them 
make it more stable.   
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Fig. 4-6. Response surface model of neural network model: predicted value of ratio between theophylline and budesonide in 
combination particles. R2=0.9 
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Fig. 4-7 summarizes the particle size distribution of each sample. As can be found 
in Fig. 4-7, excipients have effects on particle size, which result in slightly bigger 
particles compared to a precipitation without excipients.  
 
Fig. 4-7. Average particle size after spray-drying with or without excipients. 
[Solution: saturated solution (about 3%, w/v); solvent: 80% Methanol+20% 
Deionised Water] 
According to Fig. 4-7, varying concentrations of surfactants from 0.05%to 0.1%, 
leads to a significant increase in average particle size of x90 indicating a particle 
agglomeration after spray drying. This phenomenon is caused by limited flow 
properties of powder, due to typical mechanical stresses increase particle surface 
energy and hence make the powder adheres. In addition, the other cause is that 
the obtained particle shape could affect interparticle forces, for instance, the flat 
surfaces of needle-like particles have a large contact surface areas. Due to this 
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characteristic, the particles would experience high interparticle forces and form 
aggregates (Fukunaka et al., 2005). This speculation is further proved by SEM. 
According to the SEM graph of Fig. 4-11, it can be seen that the spherical 
particles have needle-like crystals on the surface, which increase the contact area 
and result in high level of cohesion.   
Furthermore, as can be found in Fig. 4-7, the samples with absence or low 
amount of HPMC have larger particles. This is because excipients have different 
capability to inhibit crystallization, where HPMC has a better inhibiting effect than 
PVP. Owing to this reason, sample with PVP could lead to bigger particle size 
when compared with HPMC.  Hence, when the water soluble excipient HPMC 
was added in, the particle becomes a smaller and a better flowability. The 
mechanism of this effect is that the HPMC creates a steric barrier, which prevent 
close contact and subsequently inhibit particle growth (Raghavan et al., 2001).  
4.3.4 Crystallinity 
In this study, DSC and X-ray diffraction were applied to characterise the 
physicochemical properties of the samples in order to determine the crystal or 
cocrystal formation.  
Preliminary studies address a potential cocrystal formation of theophylline and 
budesonide using a computation of energies by STFC Chemical Database 
Service (Sci-Tech Daresbury, UK). This study reveals that some binding between 
the two molecules might occur, but a cocrystal formation would be rather unlikely.  
Fig. 4-8 is the result of DSC analysis. As shown in Fig. 4-8-A, it notices that DSC 
measurements cannot detect budesonide and theophylline melting peak in their 
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physical mixtures. This situation is caused by two main actions. Firstly, the small 
amount of budesonide, which is 20 times less than theophylline, creates no 
interpretable DSC signal. Secondly, the thermal decomposition of theophylline 
presents with melting of budesonide during the DSC study, which is consistent 
with some degree of interaction and/or miscibility between the two components, 
and resulting endotherm peak of theophylline is shifted, broadened and 
asymmetric. Furthermore, in Fig. 4-8-B-C, the shifted melting peck of theophylline 
and flatten the curve whichever in physical mixtures or after spray drying are 
detected. This phenomenon can be suggested that it is caused by HPMC and 
PVP were immiscible (Nyamweya and Hoag, 2000), resulting in a lower 
temperature shifts and deeper glass transition, subsequently affecting the peak 
of APIs melting.  
However, this change of peak cannot eliminate assumption of cocrysal. Therefore, 
polarized light microscopy was operated to detect cocrystal of theophylline and 
budesonide. Fig. 4-9 is the graph obtained from polarized light microscopy. In the 
image, two types of crystal were discovered. Due to the higher concentration of 
theophylline, theophylline performed (produces) a larger needle-like crystal than 
budesonide that is small flat crystal at the fringe. Overall DSC data and 
microscopy image provide an evidence which confirms that theophylline and 
budesonide cannot form cocrystal. The DSC graphs of single sample are shwon 
in Appendix Fig. A3. 
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A: theophylline and budesonide physical mixture; TH= theophylline; 
BU= budesonide 
 
B: Physical mixture of APIs and exipidents 
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C: Spray drying sample from TB-1 to TB-9 
Fig. 4-8. DSC curves from single APIs, physical mixtures and combined 
precipitates [Solution: saturated solution (about 3%, w/v); solvent: 80% 
Methanol+20% Deionised Water]. 
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Fig. 4-9. Polarized light microscopy image of particles which were recrystallized 
by evaporated solvent that was used for spray drying  
 
Fig. 4-10 describes the X-ray pattern of both APIs and combination particles 
with/without excipient, which was produced from X-ray diffraction measurements. 
As illustrated in Fig. 4-10, the particle shows a partly crystalline pattern with 
excipient, as excipient masking crystal peaks. Correlation of the pattern peaks to 
peaks of single substances can be done, but it does not show a consistent pattern 
for every peak. These data indicate that there might be a slight change, but it 
cannot prove neither cocrystallisation nor theophylline monohydrate in the 
sample. Therefore it is assumed that spray drying results in a coprecipitate, but 
not generation of cocrystal. The XRD patterns of single sample are exhibited in 
Appendix Fig. 4A.  
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Fig. 4-10. X-ray pattern of both APIs and combination particles with/without 
excipient [Solution: saturated solution (about 3%, w/v); solvent: 80% 
Methanol+20% Deionised Water], the blue and black patterns are raw materials 
of theophylline (TH00) and budesonide (BU00), respectively. 
1: TB-1 
2: TB-2  
3: TB-3  
4: TB-4  
5: TB-5 
6: TB-6 
7: TB-7 
8: TB-8 
9: TB-9 
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4.3.5 Morphology 
Fig. 4-11 is the SEM graph of particles containing theophylline and budesonide, 
which were produced from solutions of these APIs. The raw material of 
theophylline exhibits a needle-like shape, and budesonide is used as micronized 
material. After spray drying, the APIs form a sphere shape particles, which can 
be depicted in Fig. 4-11. When APIs precipitate together from spray drying, the 
needle-like particles become sphere-like without excipients, which is  noticeable 
in Fig. 4-11-A, and the particles produced with excipients is a part of needle-like 
adhesive to the sphere particle, which are found in Fig. 4-11 (B to I). Among them, 
Fig.4-11(B) and Fig.4-11(C) have longer needles, while Fig.4-11 (D-I) illustrates 
the number of sphere particles have increased gradually. 
 
A: No Excipients TB-1 
 
 
B: 0.05% PVP TB-2 
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C: 0.1% PVP TB-3 
 
 
D: 0.25% HPMC TB-4 
 
 
 
E: 0.25% HPMC+0.05% PVP TB-5 
 
 
F: 0.25% HPMC+ 0.1% PVP TB-6 
  
 
G: 0.5% HPMC TB-7 
 
H: 0.5% HPMC + 0.05% PVP TB-8 
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I: 0.5% HPMC + 0.1% PVP TB-9 
 
 
Fig. 4-11. Spray-dried dual particles 
[Spray drying conditions: Solution: 
saturated solution (about 3%, w/v); 
solvent: 80% Methanol+20% 
Deionised Water]. 
 
According to these observations, most particles which were obtained from the 
solvent with no or lower concentration of HPMC, are needle-like with a length of 
about 10 µm. By increasing the amount of HPMC, it makes the needles become 
shorter and flat. Particles produced from PVP solution results in a longer shape 
than the particles generated from HPMC. Conversely, the addition of PVP forms 
more regular shape of spheres, since smaller molecule PVP can rapidly touch 
the particle surfaces and act as lubricant between the particles to form a relatively 
smooth surface on particles during the spray drying. Furthermore, PVP could 
work with HPMC to enhance HPMC binding with APIs and reduce the APIs lost 
during the spray dry to generate a stable combination particle as shown in Fig. 4-
6. This result indicates that the polymers help to produce sphere shape particles. 
4.3.6 Aerodynamic behaviour 
According to the results of laser sizer and HPLC, the TB-5, TB-6, TB-8 and TB-9 
were chosen to be carried out the aerodynamic assessment, due to their smaller 
size distribution and constant ratio of TH:BU. The assessment of the aerodynamic 
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behaviour is tested using the NGI. These assessments includes: (1). disposition 
of combination particle only; (2). 80% lactose mixture; (3). 96% lactose mixture.  
The overall result of assessment is displayed in Fig. 4-12, which describes the 
FPF of each blend. According to Fig. 4-12, it can be found absence or low 
concentration of lactose result in a low FPF from 4-18% as expected due to the 
poor flowability.  
 
Fig. 4-12. Average Fine Particle Fractions (FPF) of combined particles in 
presence/absence of lactose in a physical mixture [precipitation conditions: Spray 
drying conditions: Solution: saturated solution (about 3%, w/v); solvent: 80% 
Methanol+20% Deionised Water]. 
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As most DPI formulations deal with lactose blends where coarse lactose of 
several 100 µm acts as carrier for the micronized API (Chapter 2.2.2), hence a 
mixture of combined particles with lactose was prepared and tested for its 
aerodynamic behaviour in the NGI. This study demonstrates that the capsule is 
not as completely emptied without lactose, as lactose particles in the blend might 
press the combined particles to the inner surface. Nevertheless, the performance 
of this blend is even better with respect to an FPF of 32.02% as expected in Fig. 
4-12, due to the lower interparticle adhesion forces in a lactose blend. It is also 
found that bigger amount of lactose enhances the FPF significantly and depends 
on the concentration used. This can be attributed to lactose reduces the 
interparticle forces which make the powder cohesive. This is also related to 
balance of cohesive and adhesive forces, as stronger cohesive force may 
enhance agglomerate formation and excessive adhesive forces may prevent 
elutriation of the respirable particles from the carrier surfaces, which are leading 
to upper airway deposition. 
Furthermore, it also worth to determine whether there are any effect on the FPF 
when the powder is precipitated from different solutions. By linking the discussion 
above with the SEM results as in Fig.4-11, it was interestingly found that there 
should be a difference between the powder precipitated with PVP and HPMC, as 
they show different particle sizes and slightly different shapes. This could also be 
verified that particles with lower concentration of PVP in a mixture show a 
significant 6% higher of FPF as plotted in Fig.4-12. As can be seen in Fig. 4-13, 
the deposition of the single drugs theophylline and budesonide on the stages of 
the NGI shows a very uniform distribution, indicating that both drugs are 
codeposited and has a FPF of 32.02%. Compared with the commercial product 
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Seretide® 500, which is a tertiary mix of the APIs with lactose and is distributed 
with Aeroliser®,  its resulting FPF of about 27% was found (Taki et al.).  
 
 
Fig. 4-13. Deposition of the APIs from combined particles (TB08) mixed with 96% 
lactose on the NGI stages with regard to distribution of the single substances 
[theophylline and budesonide], [precipitation conditions: Solution: saturated 
solution (about 3%, w/v); solvent: 80% Methanol+20% Deionised Water (0.5% 
HPMC, 0.05% PVP)]. 
4.4 Conclusion 
Addition of excipients during the precipitation process is essential for stabilisation 
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results showed that the excipients influence the flowability of the particles. A 
combination of PVP and HPMC in equal shares resulted in combined particles of 
theophylline and budesonide with an average particle size in the respirable range. 
The product is partly crystalline after spray drying and meets the requirement of 
pulmonary delivery. The excipients also influences the habit of the precipitate as 
well as aerodynamic behaviour of particles. 
Without further processing, the dual particles have a moderate FPF of about 14%, 
however, because of high dosage of APIs, the FPF is only 4% from the mixture 
with lower amount of lactose; nevertheless the higher amount of carrier can be 
able to remarkably increase the FPF to 32%. This is a significant improvement 
compared to the commercial product(Taki et al.). Furthermore this study shows 
that both APIs are evenly distributed throughout the stages of the NGI thus 
indicating a codeposition of both substances. The co-particles have a benefit in 
both FPF and codelivery can be achieved. Additionally, ANN models provide 
good estimation of the quantity of theophylline in solution and in the combination 
particle with small amount of data. It is an ideal tool to help the future study to 
control and optimise the formulation procedures. In summary, the technique of 
combined spray drying is an interesting approach for the production of dual 
particles, nevertheless formation of coprecipitate is not completely resolved yet. 
These experiments indicate that some optimisation studies could be carried out 
to improve dispersibility of AIPs with high dosage.
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Chapter 5 : Ultrasound Assisted to Formulate Combination 
Particles Containing Theophylline and Budesonide  
 
5.1 Introduction 
In chapter 4, the spray drying was operated to generate combination particles, 
which were sphere-like particles with constant composition. However the desired 
aerodynamic performance of these particles, which were deliveried from high 
dosage formulation, was not achieved. In order to meet this requirement, this 
chapter is devoted to analyse low density particles, i.e. porous or hollow structure 
particles. Fig. 5-1 shows the procedures on how to construct the porous particles. 
As can be seen, Fig.5-1(a) decribes the general spray drying procedures. To 
better understand the detailed process, Fig. 5-1(b) illustrates the experimental 
steps to achieve macroporous or nanostructured hollow particles using spray 
drying. It is noticable that the precursor should be nano-suspension containing 
APIs and templating particles of a defined diameter. During spray drying, 
suspension is atomized to form spherical droplets with fix concentration of 
particles. Meanwhile, the solvent of droplets is evaporated to form 
submicrometer-sized nanostructured particles. This is in constrast to the process 
to obtain practicle as shown in Fig.5-1(c) which was used in previous chapter. 
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Fig. 5-1. Particle engineering by spray-drying: (a) a general idea of the process, 
(b) and (c) tuning of the particle morphology through precursor composition and 
process conditions(Gradon and Sosnowski, 2014) 
Application of ultrasound during crystallization is known to maintain uniform 
conditions reasonably throughout the crystallization vessel (Louhi-Kultanen et al., 
2006). Application of power ultrasound to control crystallization from solution is 
known as sonocrystallization (Louhi-Kultanen et al., 2006, Dhumal et al., 2009, 
Kaerger and Price, 2004). This technique has been widely reported to produce 
nanosuspensions.  
The aim of this study is to investigate the feasibility of producing micron-sized 
combination particles of theophylline and budesonide by an ultrasonic technique. 
Our hypothesis is to conduct the process which could enhance the homogeneous 
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nucleation of APIs (theophylline and budesonide) and allows reducing the 
consumption of organic solvent and power for the production of a desirable 
particle size. This approach is based on the fact that a gradual addition of a 
solution to an antisolvent (water) in a liquid–liquid antisolvent process increases 
the degree of supersaturation. The effects of operating parameters, i.e. feed rate, 
concentration of excipients and sonication power, on the particle size of 
combination particles were examined. To obtain the best of these parameters, an 
experimental design was adopted to produce suspensions which are suitable for 
generation of combination particles via spray drying. After this process, the 
physical-chemical properties of the processed powder and its aerosol 
performance were measured.  
5.2 Materials and methodologies 
5.2.1 Materials 
The materials used in this study are same in the chapter 2.2.  
5.2.2 Preparation of the systems 
5.2.2.1 Submicron-suspension production  
The submicron suspension was obtained by ultrasound equipment. This 
methodology has been mentioned in Chapter 2.3.4.  
In each experiment, a peristaltic pump was used to feed 25 ml APIs solution with 
flow rate of 5 ml/min, and 10 ml/min to the crystalliser. Then, ultrasound was 
applied to the clear solution with the same volume of water. Table 5-1 shows the 
setting for the ultrasound at various amplitudes and pulse of 10 s with relaxation 
time of 2 s. Typically the micronization process was only run for 3min due to 
injection of small volume of solution to the anti-solvent. The temperature of the 
solution was maintained constant during this short period. 
 119 
 
The sonifier was connected to a computer. This can enable the pre-adjustment 
of important control parameters such as amplitude, pulse length and sonication 
time. The precipitation reaction was kept at 5 ◦C. The particles were produced at 
different conditions as depicted in Table 5-1. The amplitudes were set at 27%, 
and 45%. APIs solution was injected into the anti-solvent at each run. In the 
solution, solvent was formed by water and ethanol at the ratio of 20:80. The APIs 
were dissolved with various amounts of excipients to form the solutions at 
temperature of 50 ◦C (Table 5-1). The weight ratio of theophylline and budesonide 
was at 100:5 that is chosen to cover the therapeutic range of the clinical dosage 
of inhaled budesonide (Barnes et al., 2010, Evans et al., 1997), where the 
concentration of solution was about 3.5% w/v.  
5.2.2.2 Spray drying  
The processing procedures have been described in chapter 2.3.2. The 
suspension of theophylline and budesonide were dried using spray drying. The 
mixtures were kept in a sealed container and stored in a desiccator at room 
temperature for further characterisation. 
5.2.2.3 Particle characterisation methods and drug quantification 
The particle characterisation methods have been fully described in Chapter 2.4, 
such as thermal analysis (Chapter 2.4.3), XRD (Chapter 2.4.2), SEM (Chapter 
2.4.4), particle sizing (Chapter 2.4.1), and aerodynamic analysis (Chapter 2.4.7). 
Drug quantification was also illustrated in chapter 2.4.6.  
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5.3 Results and discussion 
5.3.1 Experimental design 
The effects of independent process variables namely HPMC, PVP, amplitudes, 
and feed rate on the particle size distribution of particles are presented in Table 
5-1.  
Table 5-1 Design matrix in the full factorial design with factors, and factors' 
levels. (HPMC: -1=0% w/v, 1=0.5% w/v; PVP: -1=0% w/v, 1=0.1% w/v; 
Amplitudes: -1=27%, 1=45%; Feed rate: -1=5ml/min, 1=10ml/min). 
Sample Factors  
 HPMC PVP Amplitudes Feed rate  
TB1  1  1  1  1  
TB2  1 -1  1  1  
TB3  1  1 -1  1  
TB4  1  1  1 -1  
TB5  1 -1 -1  1  
TB6  1  1 -1 -1  
TB7  1 -1  1 -1  
TB8  1 -1 -1 -1  
TB9 -1  1  1  1  
TB10 -1 -1  1  1  
TB11 -1  1 -1  1  
TB12 -1  1  1 -1  
TB13 -1 -1 -1  1  
TB14 -1  1 -1 -1  
TB15 -1 -1  1 -1  
TB16 -1 -1 -1 -1  
 
In response to screening modelling technique, a regression model was fitted to 
establish the relationship between the particle size and the variables, which is 
shown in Table 5-2, where the coefficient of the regression model and the p-value 
displays the significance of each factors.  
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Table 5-2 Summary of output  
Regression Statistics 
Multiple R 0.983108018 
R Square 0.966501376 
Adjusted R Square 0.954320058 
Standard Error 425.6136278 
Observations 16 
 
Calculated coefficient values. 
  Coefficients 
Standard 
Error P-value 
Intercept 2060.04375 106.403407 7.57066E-10 
HPMC -1860.45625 106.403407 2.24797E-09 
PVP -362.98125 106.403407 0.005811171 
Amplitudes -11.36875 106.403407 0.916835119 
Feed rate 0.51875 106.403407 0.996197372 
 
According to Table 5-2, HPMC and PVP were found as main effects on particles 
size. However, it is unknown that how co-effects were produced by HPMC, PVP, 
amplitudes and feed rates, thereby, the ANOVA analysis was applied for further 
studies. The primary purpose of ANOVA is to understand if there is an interaction 
between the independent variables on the dependent variable. In this study, 
ANOVA is applied to understand whether there is an interaction between 
 122 
 
excipients (HPMC/PVP) and processing parameters (amplitude/feed rate) on the 
observed particle size of suspension, where HPMC, PVP, amplitudes and feed 
rates are independent variables, and particle size is dependent variable. This 
model is shown in the following equation, which is a full factorial analysis model.  
Y = β0 + β1x1 + β2x2 + β3x3 + β4x4 + β12x12 + β13x13 + β14x14 + β23x23 + β24x24
+ β34x34 + β123x123 + β134x134 + β234x234 + β1234x1234 + ϵ 
(Equation 5-1) 
Where the indicator variable, x1=HPMC, x2=PVP, x3= Amplitudes, x4= Feed rate; 
the β is the regression coefficient for the main effects of factors (HPMC, PVP, 
amplitude, and feed rate),  β0 = 2060.04375, β1 = -1860.45625, β2 = -
362.98125, β3 =-11.36875, β4 =0.51875. β12  ,  β13   … β1234 are the regression 
coefficients for the interactions of variables. 
Table 5-3 is the summary of ANOVA output. As presented in Table 5-3, the p-
value (sig.) of HPMC, PVP and HPMC*PVP was less than 0.05, thus these 
variables act as the most significant factors. 
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Table 5-3 Summary of ANOVA output 
Dependent Variable:Observed 
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
HPMC 55380759.33
1 
1 55380759.33
1 
3419.352 .000 
PVP 2108086.206 1 2108086.206 130.159 .006 
Amplitudes 2067.976 1 2067.976 .128 .917 
Feed 4.306 1 4.306 .000 .996 
HPMC * PVP 1838939.406 1 1838939.406 113.541 .000 
HPMC * Amplitudes 993.826 1 993.826 .061 .811 
HPMC * Feed 4.306 1 4.306 .000 .983 
PVP * Amplitudes 11220.106 1 11220.106 .693 .429 
PVP * Feed 41056.891 1 41056.891 .000 .983 
Amplitudes * Feed 120.451 1 120.451 .000 .996 
HPMC * PVP * 
Amplitudes 
11897.356 1 11897.356 .735 .416 
HPMC * PVP * Feed 39750.391 1 39750.391 4.244 .073 
HPMC * Amplitudes * 
Feed 
256.801 1 256.801 .001 .983 
PVP * Amplitudes * 
Feed 
25082.641 1 25082.641 .004 .954 
HPMC * PVP * 
Amplitudes * Feed 
23294.391 1 23294.391 .000 .993 
Error 1992616.562 11 181146.960   
Total 1.274E8 16    
Corrected Total 59483534.37
9 
15 
   
a. R Squared = .931 (Adjusted R Squared = .871) 
 
According to regression and ANOVA analysis, it was found that excipients and 
HPMC*PVP were potential elements causing considerable effects on the particle 
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size. Therefore, it can be able to generate a mathematical model to predict 
particle size by using the following expression:  
𝑌 = 𝛽0 + 𝛽1𝑥1 + 𝛽2𝑥2 + 𝛽12𝑥12 + 𝜖                    (Equation 5-2) 
Y = 2060.04 − 1860.46x1 − 362.98x2 + 339.02x12 + ϵ 
R2=0.997 
The predicted results are descried in Table 5-4. This result was plot as 3D-scatter 
figure as can be found in Fig. 5-2, where the predicted result closes to the 
observation and has similar tendency. Moreover, the R2 of model is 0.997. 
Therefore, this finding suggests that this model has capability to estimate the 
particle size in this experiment.    
Table 5-4 The responds of model  
Sample  Results/Responds 
  Observed particle size, nm Predicted particle size, nm 
TB1  171.4 175.625 
TB2  225.4 223.55 
TB3  180.3 175.625 
TB4  171.3 175.625 
TB5  225.4 223.55 
TB6  179.5 175.625 
TB7  216.3 223.55 
TB8  227.1 223.55 
TB9  3068 3218.5 
TB10  4721 4622.5 
TB11  3168 3218.5 
TB12  3438 3218.5 
TB13  4725 4622.5 
TB14  3200 3218.5 
TB15  4378 4622.5 
TB16  4666 4622.5 
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Fig. 5-2. Predicted and observed particle size at different levels of excipients   
Following the above study, excipients was indicated as main causes on particle 
size, therefore, the diversity concentrations of excipients were used in the second 
run of experimental design that has be displayed in Table 5-5. Table 5-5 
describes the experiments were operated at a fixed amplitude of 27% and feed 
rate of 10 ml/min.  
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Table 5-5 Design matrix in the full factorial design with factors, factors' levels 
and response values. (HPMC: -1=0% w/v,0=0.25%, 1=0.5% w/v; PVP: -1=0% 
w/v, 0=0.05%, 1=0.1%) 
Sample Factors  
 HPMC PVP   
TB01 -1 -1   
TB02 -1 0   
TB03 -1 1   
TB04 0 -1   
TB05 0 0   
TB06 0 1   
TB07 1 -1   
TB08 1 0   
TB09 1 1   
 
Table 5-6 is the observed result for this study. As can be found in Table 5-6, there 
is no significant influence on the ratio of theophylline:budesonide, so the model 
was established using excipients and particle size.  
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Table 5-6 Result of experiments 
Sample  Results/Responds Ratio between theophylline and 
budesonide in suspension    Observed 
particle size, nm 
TB01   4725 21:1 
TB02   3668 20:1 
TB03   3168 19:1 
TB04   579.1 20:1 
TB05   226 21:1 
TB06   214.1 21:1 
TB07   225.4 20:1 
TB08   173.2 20:1 
TB09   171.4 21:1 
 
In order to obtain the model, firstly, the ANOVA study was used to understand 
the interaction between excipients (HPMC/PVP) on the observed particle size of 
suspension. This model is a full factorial analysis model can be formulated as 
below: 
Y = β0 + β1x1 + β2x2 + β11x11 + β22x22 + β12x12 + β112x112 + β122x122
+ β1122x1122 + ϵ 
(Equation 5-3) 
Where the indicator variable, x1 =HPMC, x2 =PVP; the β  is the regression 
coefficient for the main effects of factors (HPMC, PVP), β12 , β13  … β1234 are the 
regression coefficients for the interactions of variables. 
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Table 5-7 shows the results from the ANOVA analysis. According to Table 5-7, 
HPMC and PVP2*HPMC2 have a significant influence on particle size, where the 
sig. was less than 0.05.  
Table 5-7 The result of ANOVA analysis 
Tests of Between-Subjects Effects 
Dependent Variable:Size 
Source Type III Sum of Squares df Mean Square F Sig. 
HPMC 25792600.987 2 12896300.493 57.244 .000 
PVP 700753.887 2 350376.943 .079 .925 
HPMC2 5658920.820 1 5658920.820 1.844 .217 
PVP2 49991.220 1 49991.220 .013 .913 
HPMC*PVP 3255450.332 2 1627725.166 .409 .682 
HPMC2*PVP 3339528.332 2 1669764.166 .421 .674 
PVP2*HPMC 16738951.692 2 8369475.846 4.826 .500 
HPMC2*PVP2 2690698.082 1 2690698.082 .770 .049 
Error 1299597.907 4 324899.477   
Total 46358525.980 9    
a. R Squared = .972 (Adjusted R Squared = .937) 
Table 5-8 presents the result of regression analysis. From Table 5-8, 0.4631 of 
sig. is found and this demonstrates that PVP was not an important factor in this 
study. Thereby, HPMC and PVP2*HPMC2 were employed to build model, which 
is can be found in the following equation  
Y = β0 + β1x1 + β1122x1122 + ϵ                  (Equation 5-4) 
Y = 972.8 − 1831.83x1 + 1100.37x1122 + ϵ 
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R2=0.897 
Table 5-8 Regression analysis output 
Regression Statistics 
Multiple R 8.750E-01 
R Square 7.657E-01 
Adjusted R Square 6.876E-01 
Standard Error 1.030E+03 
Observations 9.000E+00 
Calculated coefficient values. 
  Coefficients Standard Error P-value 
Intercept 1.461E+03 3.432E+02 5.335E-03 
HMPC  -1.832E+03 4.203E+02 4.780E-03 
PVP  -3.293E+02 4.203E+02 4.631E-01 
 
A plot of observed and predicted of particle size versus excipients is shown in Fig. 
5-2. It depicts that the deviation between experimental values and predicted 
values is less than 10%. Table 5-9 illustrates that F-statistic >F-critical. All these 
characteristics demonstrate that the model is suitable for predicting particle size 
within the range examined.  
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Fig. 5-3. Predicted and observed particle size at different levels of excipients 
Table 5-9 Summary of ANOVA data. 
  df SS MS F Significance F 
Regression 2 22824378.25 11412189 15.85043816 0.004030876 
Residual 6 4319952.171 719992   
Total 8 27144330.42       
DF: degree of freedom, SS: sum of square, MS: mean sum of square, SD: standard 
deviation, F: F-statistic, Significance F: F-critical 
The data in Fig. 5-4 displays the predicted particle size with their lower and upper 
limits versus each of excipients. The lower and upper limits of particles size 
represent the minimum and maximum limits which are achieved within the range 
of operating conditions examined. These plots demonstrate that all variables are 
negatively correlated to the particle size, however, the particle size relatively 
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grows up at higher concentration of PVP. As can be observed in Fig. 5-3 and 5-
4, the best condition is to adopt processed solution containing highest 
concentration of excipients, where HPMC is 0.5% and PVP is 0.1%. However, 
the inhalable formulation requires less excipients, although the observed size of 
particles is 171.4 nm produced from highest concentration of excipients (TB09), 
the particle size of TB05 (generated from medium concentration of excipients) is 
226nm that meets the requirement of spray drying and aerodynamic 
measurement. This area also is the best range as found in Fig. 5-4.  
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b. 
Fig. 5-4. Predicted particle size (blue) with upper confidence limit (green) and 
lower confidence limit (red) versus (a) concentration of HPMC and (b) 
concentration of PVP 
5.3.2 Crystallinity 
According to the study of experimental design in chapter 5.3.1, TB05 was 
selected to be spray dried, where the dry powder was namely TB002. In order to 
compare the ultrasonic process with spray drying, the solution which was used to 
generate TB05 was adopted for spray drying to form dry powder (TB003). Sample 
TB001 was spray dried using APIs solution without excipients. In this study, DSC 
and X-ray diffraction were applied to characterise the physicochemical properties 
of the samples and to determine the crystal formation.  
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Fig. 5-5 plots the DSC results. As can be found in Fig. 5-5, DSC measurements 
suggested that it cannot detect budesonide melting peak in spray dried sample 
TB001, as small amount of it, therefore, it creates no interpretable DSC signal.  
 
Fig. 5-5. DSC curves from single APIs, physical mixtures and processed samples, 
TH=theophylline, BU=budesonide, TB001=spray dried particle without excipients; 
TB002= spray dried nanosuspension TB05; TB003=spray dried solution of TB05 
However, the endotherm signal of budesonide is explored in TB002 as depicted 
in Fig. 5-6. The results of XRD pattern reveal a strong signal belongs to 
budesonide in TB002. This also well agrees in the finding in SEM as shown in 
Fig.5-7 E, in which it can be seen that some crystal locate on the surface of 
sphere particle of TB002. According to these detections, it can be assumed that 
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higher concentration of theophylline and its xanthine group would occupy the 
hydrogen bond of polymer, thus some budesonide are miss loaded. Therefore, 
after spray drying, the budesonide crystals are formed and stay on the surface of 
particles.  
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Fig. 5-6. X-ray pattern of processed sample TB001, TB002, and TB003. 1: raw 
theophylline (TH00); 2: raw budesonide (BU00); 3: TB001; 4: TB002; 5: TB003 
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In X-ray diffraction measurements as illustrate in Fig. 5-6, the particle shows a 
partly crystalline pattern with excipient when excipient is masking with crystal 
peaks. Correlation of the pattern peaks to peaks of single substances can be 
done, but it is not consistent for every peak. These data indicate that there might 
be a slight change, but it cannot prove neither cocrystallisation nor theophylline 
monohydrate in the sample. Therefore it is assumed that spray dry results in a 
coprecipitate, but not generation of cocrystal.  
5.3.3 Morphology 
The SEM images for untreated material, spray dried samples, and TB002 
(Ultrasound treated) are shown in Fig. 5-7. The raw material of theophylline 
exhibits a needle-like shape while budesonide is used as micronized material. 
When they precipitate together, the particle is needle-like forming to sphere 
without excipients, which is similar to spray dried theophylline in Fig.5-7-C-D. As 
shown in Fig. 5-7-E, the ultrasound sample exhibits a porous shape, which is a 
part of crystal adhesive to the sphere particle. Fig. 5-7-F is the graph of the 
particles spray dried directly from solution. As can be clearly seen, these particles 
are sphere-like with smooth surface. 
Table 5-10 describes the laser diffraction result of particle size distribution. This 
result shows that the resultant samples are formed with approximate size of 0.91-
8.53µm. As a result of slight aggregation between these particles and their shape, 
ultrasound treated sample has narrower size distribution than the spray dried 
sample, and average particle sizes which are measured by laser technique, is 
around 5μm, as can been found in Table 5-10. The results confirm that it is 
suitable for inhalation drug delivery. 
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A. Raw theophylline TH 
 
C. Spray dried theophylline TH001 
 
B. Raw budesonide BU 
 
D. No Excipients TB001 
  
E. Ultrasound processed TB002 F. Spray drying from solution TB003 
 
Fig. 5-7. Spray-dried dual particles 
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Table 5-10 Particle sizes of TB001, TB002 and TB003 which are measured by 
using laser sizer. 
Sample Particle Size µm 
X10 X50 X90 
TB001 0.91±0.41 4.04±0.32 8.53±1.23 
TB002 2.68±0.62 5.35±0.33 8.42±0.94 
TB003 1.88±1.22 4.27±0.52 8.52±1.01 
 
5.3.4 Aerodynamic behaviour 
The aerosol performances of TB001, TB002, TB003, blend I, blend II, and blend 
III are presented in Table 5-11. This experiment was repeated three time for each 
analysis to ensure that the results are reliable and reproducible.
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Table 5-11 The aerodynamic properties of different preparations of resultant samples and lactose using Aeroliser® at 60 L/min 
Dispersed samples FPFloaded (%) FPFemitted 
(%) 
Capsule and device 
retention (%) 
Impaction recovery (%) MMDA 
   Theophylline  Budesndie 
TB001 7.2±1.6 23.0±0.7 14.8±2.4 93.1±0.40 58.5±0.04 5.4±0.15 
TB002 9.9±0.9 28.2 ±1.4 9.5±0.1 88.9±0.1 60.6±0.14 5.4±0.01 
TB003 14.8±1.7 32.6±2.2 6.1±0.1 75.5±0.07 69.8±0.02 4.9±0.06 
BlendI (ML001+TB001) 3.1±1.6 24.9±1.7 18.8±0.01 20.1±0.51 14.5±0.01 4.3±0.03 
BlendII(ML001+TB002) 7.8±0.8 27.0±0.5 11.8±0.004 21.7±0.08 20.5±0.01 4.3±0.10 
BlendIII(ML001+TB003) 25.8±12.3 50.0±9.8 26.5±0.02 22.9±0.39 18.2±0.01 4.4±0.38 
 140 
 
Blend I, II and III consist of formulations that comprise of TB001, TB002 and 
TB003, respectively, where all powders are blended with coarse lactose (ML001) 
particle size between 4μm and 170μm. The powders of TB003 and TB002 have 
slightly higher FPFemitted of 32.6% and 28.2%, while the TB001 has the FPFemitted 
of 23%. It has been proved that spherical nature of particles can be able to 
improve aerosol performance profile of particles due to their uniform size 
distribution and pitted particle surface (Kaerger and Price, 2004, Pilcer and 
Amighi, 2010). 
However, as shown in Table 5-11, the capsule and device retention for the dry 
powder become higher after mixing with lactose. Simultaneously, a higher loss is 
found in blended batches. It is due to the low density particle caused by polymers, 
resulting in a sample loss during the NGI measurement (Musante et al., 2002). 
Nevertheless, the higher FPFemitted of blend batches is discovered, where 
absence of lactose results in about 30% lower of FPF as expected due to the 
poor flowability. The reason is that lactose reduces the interparticle forces which 
make the powder cohesive. Blend I has a lower FPFemitted of 24.9% compared to 
blend II and blend III, which have FPFemitted of 27.0% and 50.4% respectively, as 
shown in Table 5-11.  
In the Fig. 5-8, although TB002 has a slightly higher FPFemitted of 28.2% than its 
blended batch Blend II which has 27% of FPFemitted, there are more deposition of 
Blend II in lower stages, compared to TB002. This result suggests excipients help 
to improve aerodynamic performance of particle by change the morphology of 
particles.  
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Fig. 5-8. Deposition of the APIs from combined particles 
Table 5-12 depicts the finding from the analysis of the simultaneous deposition 
of theophylline and budesonide from the combination particles formulation. It 
indicates consistent ratio all over and this is in good agreement with the 
expectation. 
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Table 5-12 The ratio of theophylline:budesonide in each stage of NGI  
 Ratio of  theophylline:budesonide in each stage of NGI 
 TB001 TB002 TB003 Blend I Blend II Blend II 
Powder 18.22±3.05 19.31±1.22 20.70±1.33 21.22±1.12 20.90±0.96 19.84±1.83 
Throat 22.50±0.68 29.70±1.33 20.54±1.75 22.72±1.42 18.40±0.29 25.07±0.52 
Pressep 31.00±3.73 79.32±1.27 25.94±1.08 17.60±1.41 20.63±0.40 22.92±1.29 
Stage 1 20.50±1.87 18.05±2.34 21.85±0.90 23.12±1.16 19.17±0.59 24.76±1.98 
Stage 2 31.90±14.98 18.24±1.93 20.56±0.13 24.43±1.22 18.98±0.63 23.94±0.93 
Stage 3 20.60±1.33 20.79±0.03 21.43±0.25 22.64±1.46 19.51±0.59 20.65±0.55 
Stage 4 23.66±3.40 25.54±1.54 24.21±0.09 21.68±1.36 19.22±2.85 23.52±2.91 
Stage 5 34.08±11.59 30.26±0.66 26.41±0.90 25.38±1.56 21.43±0.49 21.77±3.82 
Stage 6 35.66±11.46 28.26±0.84 24.93±0.04 21.43±1.13 20.33±1.41 23.21±3.09 
Stage 7 33.36±0.27 32.13±0.41 26.71±0.95 26.60±1.22 14.98±0.47 24.21±2.82 
MOC 33.59±11.40 35.08±8.59 30.74±2.28 20.00±0.00 14.84±0.00 30.83±2.53 
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According to Table 5-12, the efficiency of the spray drying and mixing of APIs 
suggests no significant influence on ratio of theophylline:budesonide, indicating 
no particle segregation occurs during the spray drying and mixing processes. All 
batches are a homogeneous mixture of both components. Furthermore, among 
of un-blended batches (TB001, TB002, and TB003), TB002 and TB003 are 
relatively more stable than TB001 in each stage, particularly, in lower stage (from 
stage 4), owing to the bond between polymer and APIs. This can be attributed to 
the explanation on why the sample TB003 more stable than TB002. This also has 
been suggested in previous discussion, there are some fine crystals of 
budesonide adhering to the surface of sphere particle in TB002 (Fig. 5-7-E). 
These crystals can be easily segregated during the airway deposition. However, 
these crystalline budesonide can get in circulatory system faster than the bonded 
budesonide does, which reduce the inflammatory cells, such as eosinophils, T 
lymphocytes, mast cells, and dendritic cells in the airway s(Barnes and Adcock, 
2003) fast. The theophylline can relatively slow to be separated from polymer to 
inhibit resistance of steroid in COPD (Barnes, 2003). This mechanism has a 
potentiality to improve the therapeutic efficiency and reduce the side effects of 
theophylline. Additionally, the loss of budesonide are decreased in Blend II. 
Thereby, it appears that ultrasonic process is not only can help to improve the 
effects of drug, but also can reduce the cost of formulation.  
Generally, APIs-lactose mixture behaves a better sedimentation, due to reduction 
of shear force by lactose (Coates et al., 2005, 2006). Combination particle TB002 
has an FPFemitted of 27%. Compared with  the commercial product Seretide® 500, 
it is a tertiary mix of the APIs with lactose and it is distributed with Aeroliser®, 
resulting FPF of about 27% was found (Taki et al.).  
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5.4 Conclusion 
By introducing an anti-solvent ultrasonic process after the spray drying is an 
efficient technique for the production of micronized and generation of combination 
particles of theophylline-budesonide which is suitable for inhalation drug delivery. 
Conducting the ultrasound in designed experiments decreases ultrasonic power 
and consumption, feed rate, and excipients in the process. The analysis discover 
that the excipient is the significant factor that associate to particle size of sub-
micro suspensions. According to the experimental design, the selected 
parameters of ultrasonic process are applied to generate dry powder through 
spray drying.  
The sphere-shaped particles with size distribution of 0.91–8.53 μm are achieved 
after spray drying. The particle characteristic of combination produced by this 
process is suitable for inhalation drug delivery. The aerosol performance of 
ultrasound processed combination particles is 27% of FPF after blending with 
lactose. This is a similar to the commercial product (Taki et al.). Furthermore, this 
study also shows that both APIs are evenly distributed throughout the stages of 
the NGI. This is indicating a codeposition of both substances and the co-particles 
which have a benefit in both FPF and codelivery can be achieved. However, it 
should be noticed that the dosage of commercial product Seretide® 500 is 50 µg 
of salmeterol and 500 µg of fluticasone propionate, while this proposed study 
uses formulation contains 6mg of theophylline and 300 µg of budesonide.  By 
comparing both dosages, this study has opened an alternative avenue to tackle 
the research challenge of using higher dosage and greater ratio of APLs in 
generating inhalation formulation.  
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In conclusion, ultrasound is an ideal tool to help the future study to control and 
optimise the formulation procedures. These experiments indicate that some 
optimisation studies could be carried out to improve dispensability of AIPs with 
high dosage. This leads to conclude that the proposed technique of combined 
spray dry is an interesting approach for the production of dual particles. Moreover, 
spray dry technology also can be recommended as a potential methodology to 
form combination particle.  
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Chapter 6: General Discussion and Future Works  
 
6.1 Introduction   
The objective of pharmaceutical engineering of inhalation dosage forms is the 
generation of a drug product that enable the delivery of medicines efficiently and 
effectively to the human airways. Currently, the processing of these dosage forms 
remains highly empirical, which corresponds with high failure rates of these drug 
products during development and manufacturing. The primary source of dry 
powder inhaler (DPI) formulation failure is the lack of control on key 
physicochemical properties of the actives ingredients, which can be related to the 
process of micronization that is used to generate respirable particles. To fill in this 
knowledge gap, the methodologies to control the specific performance and 
stability properties of DPI dosage forms have been proposed. To achieve this 
goal, the central design principle in DPI manufacturing has to focus on design of 
particle interfaces, leading to enable careful control of particle-particle 
interactions and enhance drug product performance. 
This principle must be taken one-step further with respect to combined inhalation 
products, which are significantly more complicated than binary formulations. As 
asthma and COPD are two common conditions of the airways, the most effective 
treatment for reducing smooth muscle dysfunction and inflammation is to use 
combined therapy of corticosteroid (ICS) and theophylline (TH) together in order 
to illicit significant clinical advantages. It has been demonstrated that addition of 
oral theophylline to an inhaled corticosteroid (ICS) is superior to ICS alone in 
achieving anti-inflammation (Ito et al., 2002). Furthermore, there is evidence to 
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suggest that patients with COPD may also benefit from combined inhalation 
therapy with TH and ISC (Spears et al., 2009). 
The improved clinical outcome on therapy on combined inhaled ICS and oral TH 
is reported. The results suggested it enhances the efficiency of corticosteroids 
and recovers their anti-inflammatory actions in COPD treatment (Lim et al., 2000, 
Spears et al., 2009, Ford et al., 2010). The opportunity for synergistic action is 
enhanced by co-deposition of both particles on the same cells of the airways. 
Moreover, inhalation of TH would be an ideal delivery methodology to avoid the 
side effects caused by high concentration of TH; and slower and uncontrollable 
metabolism yield by its oral administration, leading to better bioavailability and 
treatment performance (Cosio et al., 2004). Therefore, administration of the two 
drugs by a single inhaler would lead to an increased chance for co-deposition 
compared with administration via two separate inhalers. However, current 
combined inhalation products are subject to a greater variability in dose delivery 
of each active ingredient (Kumon et al., 2010, Corrigan et al., 2006, Tajber et al., 
2009b). Hence, there is a requirement of processes that may enable production 
of combination inhaled products that will allow both drugs to be delivered more 
effectively and independently of dose variations. 
6.2 Summary 
Following physical characterisation of the materials utilised in the study, 
compared ultrasonic, spray drying, and physical mixture, the development of the 
ultrasonic and spray drying process in the lab-scale size was successfully 
achieved by controlling excipients. Many factors, including amplitudes, solvents, 
feed rates and temperatures, did not have significant effect on properties of 
 149 
 
resultant materials. As a result, a laboratory spray drying and ultrasonic system 
were proposed to enable the formation of small scale batches with a significant 
level of control and manipulation of excipients.  
In this study, the spray drying, jet milling, and wet milling process was used 
initially to generate single drug particles and the result found that they reduce the 
material down to micro size range, especially, spray drying was possible to modify 
morphology of theophylline with suitable properties for the inhaled drug. 
Moreover, theophylline spray dried particles were found to outperform micronized 
theophylline particles as determined by in vitro performance testing. Furthermore, 
urchin-like shape crystalline particles of theophylline with geometric diameter of 
0.74-74.78 μm were produced, which were found to help more budesonide 
deposit in lower stage that is 2 fold higher than jet milled theophylline.  
Secondly, the spray drying process was also used to produce individual particle 
of two active ingredients. This allows effective delivery of combination 
medicaments and independently of dose variation. All physicochemical 
characterisation results demonstrated that the spray dried combination particles 
of TH and BU were successfully co-processed into individual particles with 
crystalline properties. According to the statistics analysis, it found that the spray 
drying process parameter didn’t have significant effects on particles size. This 
can be attributed to the cause of the relatively low concentration of solutions. 
From the findings via regression and ANN analysis, HPMC has more significant 
effects on solubility of theophylline at room temperature when it is compared to 
PVP. ANOVA analysis suggested that HPMC, PVP, and PVP2 * HPMC are 
important variables to theophylline solubility. However it found null effects on 
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particle size and composition when implementing the regression model. 
Nevertheless, ANN model proves that HPMC and PVP were important factors to 
solubility of theophylline with better predicable model (R2 was 0.90; regression 
model of R2 is 0.86). Moreover, ANN also found that there were some 
associations between polymers and particle compositions. The ratio between 
theophylline and budesonide becomes more stable when exposed to higher 
concentration of excipients. Additionally, the stage by stage studies of in vitro 
performance strongly confirmed that all formulations exhibit a constant delivery 
and independently of dose variation. 
In addition, the combined drug particles of BU and TH were produced via the 
ultrasonic system. The amplitude and feed rate were controlled in this study, but 
there was no evident shown amplitude and feed are significantly related to the 
particle size (p≥1) according to ANOVA analysis. For the combination drugs, it 
has been demonstrated that the combination particles of TH:BU formulation was 
significantly (p<0.05) greater than a micronized TH:BU formulation. The 
ultrasonic combination TH:BU particles were more consistent in the delivery of 
both active ingredients than micronized sample. After blending with lactose the 
performance of the TH:BU combination particles was remarkably improved, 
which may be related to the fact that the shear force breaking agglomerated 
powders into individual particles. This approach, however, presents itself as novel 
means to produce inhaled combination dosage forms which may lead to enhance 
clinical efficacy. 
In conclusion, the ultrasonic and spray drying process has been successfully 
utilised in modifying the surface morphology of crystalline particles suitable for 
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pulmonary drug delivery. This proposed technique has been successfully 
developed by controlling all crucial factors which are identified in the system. 
Furthermore, the process has been successfully employed to engineer drug 
particles with optimum properties for delivery to the lungs. In individual particle, 
the particle characterisations revealed that theophylline and budesonide are co-
processed into each particles. However, the micronized budesonide located on 
surface of combination particles that was characterized by XRD, DSC and SEM 
in ultrasonic sample, which was not detected in spray dried product. This feature 
helps to enhance the delivery of budesonide into lower stage in NGI, thus 
ultrasonic sample has a higher FPF of budesonide than spray dried product. 
Moreover, the in vitro performance study strongly confirmed that the combined 
formulations are stable and perform uniform deposition in each stage of NGI. 
Nevertheless, according to in vitro analysis, aerodynamic performance of 
ultrasonic produced formulation is significantly greater than spray dried 
formulation by 2 fold or more, due to ultrasonic particle has rougher surface than 
spray dried one using same concentration of excipients, which leads to a better 
flowability. Therefore, the ultrasound process are progressively utilised to 
produce combination particles of two active ingredients which would allow the 
delivery of combination medicaments effectively and achieve independently of 
dose variation. Combination dosage form for respiratory products is a novel 
means to achieve an advanced drug actions and effects. 
6.3 Further works 
According to these data presented in the thesis, the ultrasonic process shows 
significant promise for generating combination particles for delivery to the lungs. 
In Chapter 5 and 6, it can be found that the particle engineering via the ultrasonic 
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and spray drying processes lead to an important opportunity to generate particles 
containing two or more active ingredients, which will allow an effective delivery of 
combination medicaments and independently of dose variation. As conditions 
such as COPD are multi-factorial (Albert and Calverley, 2008), a further 
development of this approach may investigate the potential of these processes 
to generate particles with multiple active ingredients in one particle (Kumon et al., 
2010). It would be beneficial to design the work by adding another essential drug 
to generate triple drug particles in order to formulate the pulmonary dosage form 
to help prevent COPD and asthma patients for the long-term treatment.  
However, the high dosage of theophylline results in poor flowability, which 
requires high amount of lactose to improve the aerodynamic behaviour (Chapter 
3, 4, 5). This is not suitable for DPIs delivery. Therefore, the future work could 
consider the non-carrier formulation. It is believe that such proposed work can be 
able to achieve through controlling the morphology of particles. In chapter 3, it 
was found that spray dried product of theophylline forms like urchin shape, it is 
possible to generate a large size and low density of urchin-like particles 
containing crystalline TH and BU via spray drying. This type of particles could 
contribute to a smaller aerodynamic diameter and a lower cohesiveness, thus to 
enhance the flowability and the aerosol performance of powders.  
Finally, according to Chapter 5, a sphere-like particle is obtained. This result 
indicates a possibility to generate a type of porous particles. These particles have 
a lower density, well meet the requirement of pulmonary delivery, and specially 
help reduce carrier using in the process.  In order to produce this type of particles, 
generation of high quality nano-scale suspensions is an initial step. As discussed 
in Chapter 5, ultrasonic technical is a type of bottom-up approach for production 
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of nano-suspension (Van Eerdenbrugh et al., 2008). However, this procedure is 
more suitable for the soluble APIs, rather than the slightly soluble or insoluble 
compound (theophylline and budesonide). This is shown in Chapter 5 that there 
was a sample lost after spray drying, due to the low concentration of suspension. 
Therefore, in the future, a top-down approach can be applied, such as media 
milling and high-pressure homogenization (Van Eerdenbrugh et al., 2008).  This 
technique can be able to process large amount sample and obtain a uniform 
suspension, which would be a novel method to produce combination particles 
that particularly useful for the insoluble compounds.  
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Appendix  
 
 
 
 
Figure A1 NGI result of powders mixed with different grade of lactose (ultrasonic 
sample TB002 and spray dry TB003) 
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B 
Figure A2 DVS profiles of TH00, TH01 and TH02. A: the weight changes of theophyllines 
at RH=90%; B: sorption-desorption curve of TH01 at day0 and day1. TH00: raw material; 
TH01: jet milled sample produced by low feed rate; TH02: jet milled sample produced by 
high feed rate 
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Figure A3 DSC of spray dried samples in Chapter 4 
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TB-9: HPMC=0.5%; PVP=0.1% 
Figure A4 spray dried samples in Chapter 4  
 
 
 
TB-9
Operations: Y Scale Add 1771 | Import
theophylline - File: theophylline-121110-01.raw - Type: 2Th/Th locked - Start: 3.000 ° - End: 50.000 ° - Step: 0.010 ° - Step time: 1. s - Temp.: 25 °C (Room) - Time Started: 10 s - 2-Theta: 3.000 ° - Theta: 1.500 ° - Chi: 0.00 ° - Phi: 0
Operations: Import
budesonide - File: Budesonide-121110-01.raw - Type: 2Th/Th locked - Start: 3.000 ° - End: 50.000 ° - Step: 0.010 ° - Step time: 1. s - Temp.: 25 °C (Room) - Time Started: 13 s - 2-Theta: 3.000 ° - Theta: 1.500 ° - Chi: 0.00 ° - Phi: 0.
Operations: Y Scale Add 794 | Import
TB-9 - File: TB-9.raw - Type: 2Th/Th locked - Start: 3.000 ° - End: 50.000 ° - Step: 0.010 ° - Step time: 1. s - Temp.: 25 °C (Room) - Time Started: 14 s - 2-Theta: 3.000 ° - Theta: 1.500 ° - Chi: 0.00 ° - Phi: 0.00 ° - X: 0.0 mm - Y: 0.0 
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Table A1 observed result of spray drying. IT: inlet temperature, FR: feed rate, A: 
atomization, AS: air flow rate, size: particle size, Ratio: ratio between theophylline and 
budesonide in particles.  
HMPC PVP IT FR A AS Size(µm) stv ratio stv 
-1 -1 -1 -1 -1 -1 19.11 ±2.72 14.2 ±3.67 
-1 -1 -1 -1 -1 1 11.56 ±1.23 14.89 ±4.21 
-1 -1 -1 -1 1 -1 11.01 ±3.10 14.72 ±1.43 
-1 -1 -1 -1 1 1 8.19 ±2.80 14.9 ±3.33 
-1 -1 -1 1 -1 -1 16.24 ±1.32 16.32 ±1.24 
-1 -1 -1 1 -1 1 10.98 ±2.46 14.24 ±4.20 
-1 -1 -1 1 1 -1 13.12 ±4.23 15.98 ±2.42 
-1 -1 -1 1 1 1 11.52 ±2.43 13.89 ±0.98 
-1 -1 1 -1 -1 -1 14.52 ±3.12 14.02 ±6.21 
-1 -1 1 -1 -1 1 10.32 ±0.52 14.98 ±1.75 
-1 -1 1 -1 1 -1 10.58 ±1.89 15.92 ±3.11 
-1 -1 1 -1 1 1 11.8 ±3.63 14.21 ±1.92 
-1 -1 1 1 -1 -1 11.22 ±1.83 15.26 ±3.10 
-1 -1 1 1 -1 1 9.72 ±2.51 14.52 ±4.21 
-1 -1 1 1 1 -1 11.63 ±2.72 15.21 ±3.71 
-1 -1 1 1 1 1 12.2 ±1.52 14.74 ±2.03 
-1 1 -1 -1 -1 -1 15.54 ±3.61 16.14 ±3.16 
-1 1 -1 -1 -1 1 11.54 ±1.53 15.92 ±4.2 
-1 1 -1 -1 1 -1 11.99 ±1.36 14.78 ±3.89 
-1 1 -1 -1 1 1 15.62 ±2.36 16.94 ±2.32 
-1 1 -1 1 -1 -1 15.9 ±2.74 17.23 ±3.77 
-1 1 -1 1 -1 1 8.09 ±1.47 16.32 ±5.21 
-1 1 -1 1 1 -1 10.2 ±4.12 19.23 ±2.22 
-1 1 -1 1 1 1 11.9 ±2.83 16.92 ±1.62 
-1 1 1 -1 -1 -1 13.23 ±3.21 16.34 ±4.67 
-1 1 1 -1 -1 1 15.8 ±1.55 15.78 ±0.87 
-1 1 1 -1 1 -1 13.92 ±0.92 16.77 ±3.60 
-1 1 1 -1 1 1 14.03 ±3.18 18.9 ±1.63 
-1 1 1 1 -1 -1 13.27 ±1.06 16.91 ±5.82 
-1 1 1 1 -1 1 10.13 ±2.77 15.89 ±2.17 
-1 1 1 1 1 -1 13.48 ±3.12 16.92 ±4.09 
-1 1 1 1 1 1 13.8 ±4.00 14.92 ±2.72 
1 -1 -1 -1 -1 -1 10.78 ±5.22 18.29 ±4.21 
1 -1 -1 -1 -1 1 10.04 ±3.99 16.98 ±3.82 
1 -1 -1 -1 1 -1 7.23 ±3.16 18.55 ±3.01 
1 -1 -1 -1 1 1 8.99 ±0.33 19.4 ±1.61 
1 -1 -1 1 -1 -1 10.1 ±3.41 17.09 ±3.11 
1 -1 -1 1 -1 1 6.89 ±2.98 18.67 ±4.02 
1 -1 -1 1 1 -1 8.03 ±1.63 21.09 ±2.98 
1 -1 -1 1 1 1 7.53 ±2.11 19.65 ±0.97 
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1 -1 1 -1 -1 -1 11.03 ±1.42 20.94 ±2.13 
1 -1 1 -1 -1 1 10.78 ±3.16 17.98 ±1.36 
1 -1 1 -1 1 -1 10.55 ±1.32 19.87 ±3.26 
1 -1 1 -1 1 1 9.03 ±2.15 18.99 ±2.86 
1 -1 1 1 -1 -1 10.11 ±5.21 17.53 ±1.54 
1 -1 1 1 -1 1 10.93 ±2.74 18.32 ±3.22 
1 -1 1 1 1 -1 7.49 ±1.59 20.51 ±3.90 
1 -1 1 1 1 1 7.99 ±2.61 18.42 ±2.92 
1 1 -1 -1 -1 -1 9.78 ±4.21 21.04 ±1.09 
1 1 -1 -1 -1 1 7.88 ±2.3 19.63 ±2.11 
1 1 -1 -1 1 -1 8.06 ±1.90 23.58 ±1.89 
1 1 -1 -1 1 1 5.76 ±0.63 20.1 ±2.16 
1 1 -1 1 -1 -1 8.13 ±3.26 18.99 ±1.14 
1 1 -1 1 -1 1 6.29 ±2.11 18.26 ±2.31 
1 1 -1 1 1 -1 6.06 ±1.52 18.09 ±1.09 
1 1 -1 1 1 1 6.9 ±3.56 20.85 ±3.26 
1 1 1 -1 -1 -1 9.05 ±2.75 19.52 ±1.08 
1 1 1 -1 -1 1 10.07 ±3.17 20.96 ±2.51 
1 1 1 -1 1 -1 8.42 ±4.02 18.93 ±1.44 
1 1 1 -1 1 1 7.9 ±2.63 19.03 ±1.96 
1 1 1 1 -1 -1 10.63 ±1.99 19.95 ±3.41 
1 1 1 1 -1 1 6.68 ±3.86 19.03 ±2.91 
1 1 1 1 1 -1 7.11 ±3.32 18.99 ±2.90 
1 1 1 1 1 1 6.97 ±2.29 19.54 ±3.01 
 
Table A2  Regression (dependent: size) 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
1 (Constant) 10.552 .235  44.984 .000 10.083 11.022 
HPMC -2.015 .235 -.702 -8.590 .000 -2.485 -1.545 
PVP -.111 .235 -.039 -.472 .639 -.581 .359 
IT .210 .235 .073 .895 .375 -.260 .680 
FR -.514 .235 -.179 -2.189 .033 -.983 -.044 
A -.583 .235 -.203 -2.486 .016 -1.053 -.114 
AS -.620 .235 -.216 -2.644 .011 -1.090 -.150 
a. Dependent Variable: size 
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Table A3 regression (dependent: ratio TH/BU) 
 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% Confidence 
Interval for B 
B Std. Error Beta 
Lower 
Bound 
Upper 
Bound 
1 (Constant) 17.542 .142  123.222 .000 17.257 17.827 
HPMC 1.795 .142 .806 12.607 .000 1.510 2.080 
PVP .658 .142 .296 4.623 .000 .373 .943 
IT -.048 .142 -.022 -.338 .737 -.333 .237 
FR -.058 .142 -.026 -.408 .685 -.343 .227 
A .288 .142 .129 2.020 .048 .002 .573 
AS -.237 .142 -.106 -1.662 .102 -.522 .049 
a. Dependent Variable: ratio 
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Table A4 ANOVA analysis (dependent size) 
Tests of Between-Subjects Effects 
Dependent Variable:size 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 527.151a 62 8.502 23.717 .162 
Intercept 7126.525 1 7126.525 19878.645 .005 
HPMC 259.895 1 259.895 724.947 .024 
PVP .785 1 .785 2.191 .378 
IT 2.818 1 2.818 7.861 .218 
FR 16.882 1 16.882 47.090 .092 
AS 24.614 1 24.614 68.658 .076 
A 21.774 1 21.774 60.736 .081 
AS * A 27.812 1 27.812 77.580 .072 
FR * A 5.388 1 5.388 15.030 .161 
HPMC * A 2.628 1 2.628 7.332 .225 
IT * A 4.075 1 4.075 11.368 .184 
PVP * A 4.813 1 4.813 13.424 .170 
FR * AS 1.185 1 1.185 3.306 .320 
HPMC * AS 3.915 1 3.915 10.922 .187 
IT * AS 8.636 1 8.636 24.090 .128 
PVP * AS 1.229 1 1.229 3.429 .315 
HPMC * FR .072 1 .072 .201 .731 
IT * FR .095 1 .095 .266 .697 
PVP * FR 2.735 1 2.735 7.629 .221 
HPMC * IT 5.730 1 5.730 15.983 .156 
HPMC * PVP 20.851 1 20.851 58.161 .083 
PVP * IT 4.136 1 4.136 11.537 .182 
FR * AS * A 2.628 1 2.628 7.332 .225 
HPMC * AS * A 10.441 1 10.441 29.124 .117 
IT * AS * A 8.888 1 8.888 24.792 .126 
PVP * AS * A .159 1 .159 .444 .626 
HPMC * FR * A 3.511 1 3.511 9.793 .197 
IT * FR * A .468 1 .468 1.304 .458 
PVP * FR * A 1.437 1 1.437 4.008 .295 
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HPMC * IT * A 6.976 1 6.976 19.459 .142 
HPMC * PVP * A 2.469 1 2.469 6.887 .232 
PVP * IT * A 1.349 1 1.349 3.761 .303 
HPMC * FR * AS .110 1 .110 .306 .678 
IT * FR * AS .022 1 .022 .062 .845 
PVP * FR * AS 4.280 1 4.280 11.938 .179 
HPMC * IT * AS 3.906 1 3.906 10.894 .187 
HPMC * PVP * AS 6.357 1 6.357 17.731 .148 
PVP * IT * AS .905 1 .905 2.524 .358 
HPMC * IT * FR .051 1 .051 .143 .770 
HPMC * PVP * FR 3.827 1 3.827 10.675 .189 
PVP * IT * FR .803 1 .803 2.241 .375 
HPMC * PVP * IT 4.500 1 4.500 12.551 .175 
HPMC * FR * AS * A .603 1 .603 1.681 .418 
IT * FR * AS * A .356 1 .356 .992 .501 
PVP * FR * AS * A 5.935 1 5.935 16.556 .153 
HPMC * IT * AS * A 1.635 1 1.635 4.561 .279 
HPMC * PVP * AS * A .028 1 .028 .077 .828 
PVP * IT * AS * A 1.116 1 1.116 3.112 .328 
HPMC * IT * FR * A 2.702 1 2.702 7.537 .222 
HPMC * PVP * FR * A 2.980 1 2.980 8.312 .213 
PVP * IT * FR * A 3.335 1 3.335 9.303 .202 
HPMC * PVP * IT * A 2.013 1 2.013 5.615 .254 
HPMC * IT * FR * AS .024 1 .024 .068 .837 
HPMC * PVP * FR * AS 4.542 1 4.542 12.670 .174 
PVP * IT * FR * AS 3.023 1 3.023 8.433 .211 
HPMC * PVP * IT * AS .630 1 .630 1.757 .411 
HPMC * PVP * IT * FR .622 1 .622 1.735 .413 
HPMC * IT * FR * AS * A .024 1 .024 .068 .837 
HPMC * PVP * FR * AS * 
A 
.383 1 .383 1.068 .490 
PVP * IT * FR * AS * A .963 1 .963 2.686 .349 
HPMC * PVP * IT * AS * A 7.583 1 7.583 21.152 .136 
HPMC * PVP * IT * FR * A .817 1 .817 2.278 .373 
HPMC * PVP * IT * FR * 
AS 
4.682 1 4.682 13.059 .172 
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Error .359 1 .359   
Total 7654.035 64    
Corrected Total 527.510 63    
a. R Squared = .999 (Adjusted R Squared = .957) 
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Table A5 ANOVA analysis (dependent ration between theophylline and budesonide in 
particles) 
Tests of Between-Subjects Effects 
Dependent Variable:ratio 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 317.019a 62 5.113 798.940 .028 
Intercept 19693.912 1 19693.912 3077173.785 .000 
HPMC 206.138 1 206.138 32209.032 .004 
PVP 27.720 1 27.720 4331.285 .010 
IT .148 1 .148 23.160 .130 
FR .216 1 .216 33.785 .108 
AS 3.582 1 3.582 559.618 .057 
A 5.290 1 5.290 826.562 .062 
AS * A .002 1 .002 .282 .189 
FR * A .093 1 .093 14.535 .163 
HPMC * A .644 1 .644 100.626 .363 
IT * A 1.729 1 1.729 270.191 .239 
PVP * A .429 1 .429 67.035 .097 
FR * AS .788 1 .788 123.071 .157 
HPMC * AS .011 1 .011 1.723 .114 
IT * AS .002 1 .002 .353 .259 
PVP * AS .620 1 .620 96.899 .164 
HPMC * FR 3.019 1 3.019 471.704 .129 
IT * FR 1.334 1 1.334 208.441 .344 
PVP * FR 1.243 1 1.243 194.254 .246 
HPMC * IT .003 1 .003 .431 .630 
HPMC * PVP 2.933 1 2.933 458.228 .030 
PVP * IT 1.051 1 1.051 164.160 .450 
FR * AS * A .522 1 .522 81.563 .170 
HPMC * AS * A .000 1 .000 .035 .082 
IT * AS * A .089 1 .089 13.829 .167 
PVP * AS * A 1.216 1 1.216 189.923 .146 
HPMC * FR * A 1.544 1 1.544 241.220 .341 
IT * FR * A .137 1 .137 21.391 .136 
PVP * FR * A .260 1 .260 40.641 .399 
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HPMC * IT * A 3.106 1 3.106 485.376 .229 
HPMC * PVP * A 2.504 1 2.504 391.298 .132 
PVP * IT * A .270 1 .270 42.250 .197 
HPMC * FR * AS 8.556 1 8.556 1336.816 .117 
IT * FR * AS .047 1 .047 7.392 .224 
PVP * FR * AS .089 1 .089 13.829 .167 
HPMC * IT * AS .060 1 .060 9.379 .201 
HPMC * PVP * AS .024 1 .024 3.754 .303 
PVP * IT * AS .842 1 .842 131.532 .055 
HPMC * IT * FR 1.939 1 1.939 302.978 .137 
HPMC * PVP * FR 1.507 1 1.507 235.431 .441 
PVP * IT * FR .483 1 .483 75.473 .473 
HPMC * PVP * IT .693 1 .693 108.290 .061 
HPMC * FR * AS * A .078 1 .078 12.250 .177 
IT * FR * AS * A 6.250E-6 1 6.250E-6 .001 .280 
PVP * FR * AS * A .907 1 .907 141.759 .153 
HPMC * IT * AS * A .000 1 .000 .016 .921 
HPMC * PVP * AS * A .090 1 .090 14.063 .166 
PVP * IT * AS * A .025 1 .025 3.876 .299 
HPMC * IT * FR * A 2.038 1 2.038 318.399 .336 
HPMC * PVP * FR * A .439 1 .439 68.579 .277 
PVP * IT * FR * A .416 1 .416 65.004 .679 
HPMC * PVP * IT * A .056 1 .056 8.813 .207 
HPMC * IT * FR * AS 2.265 1 2.265 353.910 .134 
HPMC * PVP * FR * AS .585 1 .585 91.441 .566 
PVP * IT * FR * AS 3.413 1 3.413 533.321 .128 
HPMC * PVP * IT * AS 1.677 1 1.677 262.035 .439 
HPMC * PVP * IT * FR 7.196 1 7.196 1124.345 .119 
HPMC * IT * FR * AS * A .403 1 .403 63.004 .480 
HPMC * PVP * FR * AS * 
A 
13.506 1 13.506 2110.254 .114 
PVP * IT * FR * AS * A .439 1 .439 68.579 .477 
HPMC * PVP * IT * AS * A .245 1 .245 38.285 .102 
HPMC * PVP * IT * FR * A 1.645 1 1.645 257.001 .140 
HPMC * PVP * IT * FR * 
AS 
.714 1 .714 111.566 .460 
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Error .006 1 .006   
Total 20010.938 64    
Corrected Total 317.026 63    
a. R Squared = 1.000 (Adjusted R Squared = .999) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
